

(12) 特許協力条約に基づいて公開された国際出願

(19) 世界知的所有権機関
国際事務局

(43) 国際公開日
2022年11月17日(17.11.2022)



(10) 国際公開番号

WO 2022/239704 A1

(51) 国際特許分類:

C07K 1/16 (2006.01) *C07K 17/04* (2006.01)
C07K 16/18 (2006.01) *C12N 15/13* (2006.01)

(21) 国際出願番号: PCT/JP2022/019548

(22) 国際出願日: 2022年5月6日(06.05.2022)

(25) 国際出願の言語: 日本語

(26) 国際公開の言語: 日本語

(30) 優先権データ:

特願 2021-079977 2021年5月10日(10.05.2021) JP

(71) 出願人: 株式会社カイオム・バイオサイエンス (**CHIOME BIOSCIENCE INC.**) [JP/JP]; 〒1510071 東京都渋谷区本町三丁目12番1号 Tokyo (JP).

(72) 発明者: 吉森 孝行 (**YOSHIMORI Takayuki**); 〒1510071 東京都渋谷区本町三丁目12番1号 株式会社カイオム・バイオサイエンス内 Tokyo (JP). アイルソ ステファン (**IARUSSO Stefan**); 13086 ベルリン ハーバー・ベイヤール8番地 Berlin (DE).

(74) 代理人: 小林 浩, 外 (**KOBAYASHI Hiroshi et al.**); 〒1040028 東京都中央区八重洲二丁目8番7号 福岡ビル9階 阿部・井窪・片山法律事務所 Tokyo (JP).

(81) 指定国(表示のない限り、全ての種類の国内保護が可能): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP,

KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) 指定国(表示のない限り、全ての種類の広域保護が可能): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), ユーラシア (AM, AZ, BY, KG, KZ, RU, TJ, TM), ヨーロッパ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

添付公開書類:

- 一 国際調査報告(条約第21条(3))
- 一 明細書の別個の部分として表した配列リスト(規則5.2(a))

(54) **Title:** PURIFICATION METHOD OF ANTIBODY COMPOSITION

(54) 発明の名称: 抗体組成物の精製方法

(57) **Abstract:** The present invention addresses the problem of providing a method for eliminating a glycosylation isomer from an antibody drug, etc. The present invention provides, for example, a purification method of an antibody composition, said purification method comprising loading the antibody composition on a conventional chromatography so as to allow the chromatography support to adsorb an antibody which has no sugar chain attached to a site other than the Fc region glycosylation consensus region, eluting the support with an elution solvent and thus eluting the antibody adsorbed on the support to thereby give a purified antibody composition.

(57) 要約: 本発明は、抗体医薬品の糖鎖付加異性体を除去する方法等の提供を課題とする。本発明は、例えば、抗体組成物の精製方法であって、前記抗体組成物をコンベンショナルクロマトグラフィに負荷して、Fc領域糖鎖付加コンセンサス領域以外の部位に糖鎖が付加していない抗体をクロマトグラフィ担体に吸着させること、及び前記担体を溶出液で溶出させることにより、前記担体に吸着した前記抗体を溶出させて精製抗体組成物を得ることを含む、前記精製方法を提供するものである。



WO 2022/239704 A1

SPECIFICATION

Title of the Invention: Purification Method of Antibody Composition

Technical Field

[0001] The present invention relates to a production method for an antibody composition. In more detail, the present invention relates to a purification method for an antibody composition with reduced levels of isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region.

Background Art

[0002] Antibody drugs comprising a monoclonal antibody as an active ingredient are expected as one of the molecular targeted drugs based on the high binding affinity and binding specificity of an antibody molecule for its antigen, and their research and development have progressed. Antibody drugs are indispensable for the treatment of various diseases including cancers and autoimmune diseases, and nearly 100 of products have now been approved and used in the world (Non-patent Document 1, Non-patent Document 2). Expectations remain high for the development of novel antibody drugs satisfying unmet medical needs, and it is further expected that many new antibody drugs will be investigated and developed.

[0003] An antibody (IgG) has an N-linked sugar chain at the Asn residue at position 297 (Asn297) in a glycosylation consensus region (Asn297-X-Ser/Thr, wherein X is an amino acid other than Pro) present in the heavy chain Fc region. Such a sugar chain present in this glycosylation consensus region is known to contribute to properties as an antibody molecule, such as biological activity, pharmacokinetics in blood, safety and so on (Non-patent Document 3, Non-patent Document 4). For example, it has been known that antibody-dependent cellular cytotoxicity (ADCC) activity is enhanced upon removal of the Fuc residue (core fucose) attached to the N-acetylglucosamine (GlcNAc) residue at the reducing end of the N-linked sugar chain at Asn297. Likewise, it has been found that a greater number of galactose (Gal) residues in the non-reducing end portion of a sugar chain linked to the Fc region are more likely to enhance binding to the first complement component (C1q), which in turn enhances complement-dependent cytotoxicity (CDC) activity (Non-patent Document 5).

[0004] On the other hand, there are also well-known cases of antibodies (glycosylation isomers) having sugar chains linked to sites other than the glycosylation consensus region in the antibody Fc region. For example, the antineoplastic agent Cetuximab produced in SP2/0 cells was confirmed to have an N-linked sugar chain linked to its Fab region (Non-patent Document 3). In addition to this, various reports have been made on glycosylation isomers (Non-patent Document 6, Non-patent Document 7, Non-patent Document 8).

[0005] Glycosylation isomers are known to have the potential to affect various antibody

properties such as biological activity (Non-patent Document 10, Non-patent Document 11), immunogenicity (Non-patent Document 8, Non-patent Document 10), blood half-life (Non-patent Document 9), etc. In particular, a sugar chain linked near an Fab region or a CDR region will raise a concern for the risk of reduced biological activity. Likewise, glycosylation isomers, i.e., antibodies having sugar chains linked to sites other than the glycosylation consensus region have a concern for safety such as immunogenicity, etc.

[0006] When biological activity is greatly reduced and/or immunogenicity is greatly increased upon attachment of sugar chains to sites other than the glycosylation consensus region, there will arise a negative effect undesirable for ingredients of antibody drugs, so that these glycosylation isomers are regarded as product-related impurities. Such product-related impurities are not desired to be contained as ingredients of drugs, and are desired to be removed as much as possible, also from a regulatory perspective (Non-patent Document 12).

[0007] When an antibody comprising a consensus sequence which may have a sugar chain attached to a site other than the glycosylation consensus region in the antibody Fc region is found as a candidate molecule for the development of drugs, it is usual to replace the consensus sequence with another amino acid sequence to ensure that no sugar chains is linked to this site. In this case, binding activity and other properties may be reduced when compared to the performance of the original antibody, and there is a possibility that an antibody having the intended therapeutic effect cannot be obtained.

[0008] Glycosylation isomers having sugar chains linked to antibody regions (e.g., Fab or CDR) other than the glycosylation consensus region can be evaluated and distinguished by being separated at the level of small-scale and high-performance analytical methods. There are known cases where peptide fragments are evaluated by high-performance liquid chromatography in combination with mass spectrometry, and where sugar chains cleaved from antibodies are evaluated directly (Non-patent Document 6, Non-patent Document 9). Moreover, another case is known where antibodies having sugar chains linked to their Fab region were analyzed by hydrophobic interaction chromatography (HIC) (Non-patent Document 13). However, these cases were all intended for analytical purpose and designed to use a very small amount of antibody and an analytical method with very high separation performance, and the composition thus separated cannot be used as an antibody drug. Moreover, a review of HIC analysis (Non-patent Document 14) discloses the usefulness of separation performance for many antibodies, but it does not suggest at all that glycosylation isomers can be separated by HIC-based purification techniques.

[0009] As described above, no method has been known for separating and removing such glycosylation isomers to prepare an antibody composition free from or with sufficiently reduced levels of isomers having sugar chains attached to sites other than the glycosylation consensus region. Namely, in conventional techniques, glycosylation isomers can merely be evaluated for their glycosylation status at the analytical level, and there has been no method for separating and removing glycosylation isomers of an antibody to produce an antibody composition in an amount sufficient to be provided as a

drug. In addition, such an antibody composition has not been known.

[0010] In view of the foregoing, in most cases where sugar chains are attached to sites other than the glycosylation consensus region present in the antibody Fc region and such glycosylation isomers are contained, these ingredients are contained as part of antibody drugs without being separated. Cetuximab mentioned above has also been developed as having the composition of a mixture having sugar chains attached to both the glycosylation consensus region in the Fc portion and a non-consensus region within Fab (Non-patent Document 3). If glycosylation isomers have no biological activity, it is not desirable because product-related impurities will be contained as ingredients of drugs.

[0011] It should be noted that there are reports on the separation of glycosylation isomers by affinity chromatography with lectin specifically binding to a certain sugar chain (Non-patent Document 15, Non-patent Document 16). This technique is designed to use Concanavalin A as a ligand and has also been found to have high separation properties. However, this technique is affinity-based separation and is not suitable for the production of drugs because of using natural substances. Thus, there is no case where this technique was applied to the production of antibody drugs.

[0012] As to techniques known to achieve the separation of sugar chain components in non-antibody proteins, there is a case where genetically recombinant antithrombins were separated by chromatography depending on differences in the number of sugar chains (Patent Document 1). In addition, genetically recombinant erythropoietins and derivatives thereof are separated by chromatography depending on differences in the number of sialic acids added (Patent Document 2). Likewise, there is a case where ovalbumin and transferrin were separated by using isoelectric focusing chromatography (Patent Document 3). However, these techniques cannot be applied directly to antibodies, and there is absolutely no report on a production method designed to separate and remove glycosylation isomers in an antibody composition.

[0013] As to techniques other than those mentioned above, it is known that sugar chains are removed by enzymatic treatment (Non-patent Document 17). However, in terms of safety, problems may arise from the separation and removal of enzymes and their origin, etc. Thus, this technique is difficult to use as a production technique for drugs. In the enzymatic removal of antibody sugar chains, it is also impossible to distinguish between sugar chains in glycosylation consensus and non-consensus regions.

[0014] The anti-hDLK-1 antibody shown in Patent Document 4 is an antibody whose antitumor activity is expected to be promising.

Prior Art Documents

Patent Documents

[0015] Patent Document 1: WO2008/120801

Patent Document 2: JP 2001-064300 A

Patent Document 3: WO2005/100379

Patent Document 4: WO2014/054820

Non-patent Documents

- [0016] Non-patent Document 1: YAKUGAKU ZASSHI 137(7), 815-816 (2017)
Non-patent Document 2: Bull. Natl. Inst. Health Sci., 132, 36-46 (2014)
Non-patent Document 3: CHROMATOGRAPHY, 34(2), 83-88 (2013)
Non-patent Document 4: Protein Cell, 9, 63-73 (2018)
Non-patent Document 5: Front. Immunol., 8 (646), 1-8 (2017)
Non-patent Document 6: J. Biol. Chem., 284 (47), 32493-32506 (2009)
Non-patent Document 7: Embo J., 10, 2717-2723 (1991)
Non-patent Document 8: J. Immunol., 196, 1435-1441 (2016)
Non-patent Document 9: Anal. Biochem., 349, 197-207 (2006)
Non-patent Document 10: Nature Review Immunology, published online, 04 Feb, (2019)
Non-patent Document 11: Biochem. J., 338 (2), 529-538 (1999)
Non-patent Document 12: ICH Q6 B Guideline
Non-patent Document 13: mAbs, 6 (4), 852-858 (2014)
Non-patent Document 14: J. Pharm. Biomed. Anal., 130, 3-18 (2016)
Non-patent Document 15: J. Biol. Chem., 285 (21), 16012-22 (2010)
Non-patent Document 16: Oncotarget, 7 (21), 31166-76 (2016)
Non-patent Document 17: J. Immunol. Methods, 467, 58-62 (2019)

Summary of the Invention

Problem to be Solved by the Invention

[0017] Sugar chains linked to sites other than the glycosylation consensus region in an antibody are also undesirable in terms of biological activity and safety, and there has been a demand for the development of techniques by which glycosylation isomers contained in antibody drugs can be removed to sufficient levels and a uniform purified antibody composition can be prepared in a simple manner. Accordingly, the present invention aims to provide a method for removing glycosylation isomers in antibody drugs.

[0018] In another aspect, the present invention aims to obtain a more effective and safer purified composition of anti-hDLK-1 antibody.

Means to Solve the Problem

[0019] As shown by the above conventional techniques, there is a report showing that glycosylation isomers were separated by precise and high-resolution chromatography for analysis and characterization purposes, but there has been no report on production techniques or preparation techniques by which glycosylation isomers in antibody drugs can be separated and removed by chromatography. As a result of extensive and intensive efforts made to solve the problems stated above, the inventors of the present invention have surprisingly found that a purified antibody composition with reduced levels of glycosylation isomers can be prepared by using a conventional hydrophobic interaction chromatography media, particularly by optimizing the conditions used for

adsorption and separation of glycosylation isomers and a desired product.

[0020] Moreover, the inventors of the present invention have made an effort to separate glycosylation isomers and purify non-glycosylation isomers for the anti-hDLK-1 antibody shown in Patent Document 4 by using the newly found method for reducing glycosylation isomers. Glycosylation isomers having sugar chains near CDRs in an antibody may affect the binding activity of the antibody, but the degree of reduction in the activity is also related to the size and positions of sugar chains linked; and hence there is also a possibility that these glycosylation isomers will not affect the activity. Surprisingly, in the anti-hDLK-1 antibody shown in Patent Document 4, the inventors of the present invention have found that glycosylation isomers completely lose activity and therefore become “impurities” in drugs. As a result, the inventors of the present invention have succeeded in identifying glycosylation isomers as new impurities in a crude anti-hDLK-1 antibody product, and have enabled the removal of these glycosylation isomers to thereby achieve the provision of a more effective and safer purified composition of anti-hDLK-1 antibody.

[0021] Namely, the present invention relates to (1) to (27) shown below.

(1) A purification method for an anti-hDLK-1 antibody composition, whose heavy chain has an amino acid sequence selected from SEQ ID NOs: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, said method comprising:

loading a crude antibody product on conventional chromatography to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the abovementioned chromatography media; and

treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition,

wherein the content of glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region in the resulting purified antibody composition is reduced when compared to the crude antibody product.

(2) The purification method according to (1) above, wherein the media of the conventional chromatography is a hydrophobic interaction chromatography media or a mixed-mode chromatography media.

(3) The purification method according to (1) or (2) above, wherein the media of the conventional chromatography has an average particle size of 15 μm or more.

(4) The purification method according to (1) or (2) above, wherein the media of the conventional chromatography has an average particle size of 20 to 100 μm .

(5) The purification method according to any one of (1) to (4) above, wherein the media of the conventional chromatography has a benzyl group or a butyl group.

(6) The purification method according to any one of (1) to (5) above, wherein the protein load per unit volume of the media of the conventional chromatography is 20 mg/mL or more.

(7) The purification method according to any one of (1) to (6) above, wherein the

media of the conventional chromatography is a hydrophobic interaction chromatography media, and wherein said method comprises, after loading the crude antibody product on the media, washing the media with a wash buffer before elution.

(8) The purification method according to (7) above, characterized in that the salt concentration of the wash buffer is 10 mM or more higher than the salt concentration of the eluent.

(9) The purification method according to (7) or (8) above, characterized in that the salt concentration of the wash buffer is 0.5 M or more.

(10) The purification method according to (7) or (8) above, characterized in that the salt concentration of the wash buffer is 1.0 M or more.

(11) The purification method according to any one of (7) to (10) above, wherein the pH of the wash buffer is 0.2 Units or more lower than the pH of the eluent and is within the range of pH 4 to 8.

(12) The purification method according to any one of (7) to (11) above, wherein the washing is accomplished by passing two or more column volumes of the wash buffer.

(13) The purification method according to any one of (7) to (12) above, characterized in that the washing and elution are accomplished by using a mobile phase whose pH or/and salt concentration change in a stepwise or linear fashion.

(14) The purification method according to any one of (7) to (13) above, wherein the eluent has a salt concentration of 0.5 M or less or contains no salt and has a pH of 5 to 7.

(15) The purification method according to any one of (1) to (14) above, wherein said method gives a yield of 20% or more.

(16) The purification method according to any one of (1) to (15) above, wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is 5% or less.

(17) The purification method according to (16) above, wherein the ratio of glycosylation isomers relative to the total antibody in the crude antibody product is higher than 5%.

(18) The purification method for an anti-hDLK-1 antibody composition according to (1) above, said method comprising:

loading the crude antibody product on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm ;

allowing the antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media;

washing the media one or more times with a wash buffer of pH 4 to 6 to remove glycosylation isomers; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

(19) The purification method for an antibody composition according to (1) above, said method comprising:

loading the crude antibody product adjusted to a salt concentration of 0.5 M or more on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm to remove glycosylation isomers into a flow-through fraction;

washing the media with a wash buffer; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

(20) The purification method for an antibody composition according to (1) above, said method comprising:

loading the crude antibody product adjusted to pH 4 to 6 on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm to remove glycosylation isomers into a flow-through fraction;

washing the media with a wash buffer; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

(21) The method according to any one of (1) to (20) above, wherein the protein load per unit volume of the media of the conventional chromatography is 20 g/L or more, and the washing is accomplished by passing five or more column volumes of the wash buffer.

(22) A production method for an antibody composition, which comprises the purification method according to any one of (1) to (21) above, wherein the ratio of an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region relative to the total antibody is 95% or more.

(23) A production method for a purified anti-hDLK-1 antibody composition, whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, said method comprising:

loading a crude antibody product on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm ;

allowing an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media;

washing the media one or more times with a wash buffer containing 0.5 M or more salt to remove glycosylation isomers; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

(24) An antibody composition produced by the production method according to (22) or (23) above.

(25) A method for removing glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region from a crude anti-hDLK-1 antibody product, whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, said method comprising:

loading the crude antibody product on a hydrophobic interaction chromatography media to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media;

washing the media with a wash buffer; and

treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition.

(26) An anti-hDLK-1 antibody composition, whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, wherein the antibody composition contains an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region at a ratio of 95% or more relative to the total antibody.

(27) An anti-hDLK-1 antibody, whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, wherein the antibody has no sugar chains attached to sites other than the Fc region glycosylation consensus region.

Effects of the Invention

[0022] The present invention enables the reduction or removal of glycosylation isomers having sugar chains attached to sites other than the glycosylation consensus region in an antibody.

[0023] As a first effect, the present invention enables the provision of an antibody composition for medical use with reduced content of glycosylation isomers. The thus purified high-purity antibody composition with reduced levels of glycosylation isomers can be formulated into pharmaceutical formulations with higher purity.

[0024] As a second effect, the present invention enables the provision of an antibody composition for medical use free from glycosylation isomers. The thus obtained

antibody composition can be provided as a composition whose active pharmaceutical ingredient is of very high purity, i.e., as a pharmaceutical composition excellent in efficacy and safety.

In particular, the purified composition of anti-hDLK-1 antibody purified in the present invention is free from inactive impurities, i.e., glycosylation isomers, and therefore can be provided as a pharmaceutical composition excellent in efficacy and safety.

Brief Description of the Drawings

[0025] Figure 1 is a graph showing an HIC-HPLC analysis pattern of the crude product obtained from the culture solution of cells producing the humanized anti-hDLK-1 monoclonal antibody.

Figure 2 is a photograph showing the results of SDS-PAGE analysis on Protein A-purified culture supernatants from CHO cells transiently expressing the humanized anti-hDLK-1 monoclonal antibody.

Figure 3 is a graph showing a separation profile of the antibody composition with the Capto Butyl hydrophobic interaction chromatography media.

Figure 4 includes a graph and table showing the results of purity analysis test by HIC-HPLC on the purified antibody composition separated with the Capto Butyl media. In the table, Peak 1 and Peak 2 each shows the ratio (%) of glycosylation isomer antibody (Peak 1 has a sugar chain linked to one CDR in the four polypeptide chains, Peak 2 has sugar chains linked to two CDRs in the four polypeptide chains), and Peak 3 shows the ratio (%) of antibody having a sugar chain linked only to the glycosylation consensus region.

Figure 5A is a graph showing a separation profile of the antibody composition with the Capto Butyl media.

Figure 5B is a graph showing a separation profile of the antibody composition with the Poros Benzyl Ultra media.

Figure 6 includes graphs showing the results analyzed by the design of experiment for control of the glycosylation isomer content by optimizing the conditions used for chromatography with the POROS Benzyl Ultra media.

Figure 7 is a diagram showing the sequence of chromatography steps in the purification process of the antibody composition.

Figure 8 is a graph showing the elution pattern, yield and purity obtained when varying the volumes of wash buffers in hydrophobic interaction chromatography (upper panel: under conditions where wash buffer 1 is 6 CV and wash buffer 2 is 5 CV; middle panel: under conditions where wash buffer 1 is 8 CV and wash buffer 2 is 5 CV; lower panel: under conditions where wash buffer 1 is 15 CV and wash buffer 2 is 5 CV).

Figure 9 shows the analysis data of HIC-HPLC analysis on components isolated from the crude antibody product by precise fractionation. Panel (a) shows the results of HIC-HPLC analysis on the crude antibody product before isolation. Panel (b) shows the results of HIC-HPLC analysis on the fraction obtained as a main peak during HIC-HPLC

in (a). Panel (c) shows the results of HIC-HPLC analysis on the fraction obtained as a pre-peak during HIC-HPLC in (a).

Figure 10 is a graph showing the results evaluated for the ADCC activity of glycosylation isomers. The vertical axis shows the fluorescence intensity indicative of ADCC activity, and the horizontal axis shows the antibody concentration. Circles represent the results of the fraction obtained as a main peak in Figure 9 (b) (glycosylation isomer-free component), squares represent the results of the fraction obtained as a pre-peak in Figure 9 (c) (glycosylation isomer), and triangles represent the results of the crude antibody product before isolation in Figure 9 (a).

Figure 11 shows the nucleotide sequence (SEQ ID NO: 37) and amino acid sequence (SEQ ID NO: 38) of the coding region for the H chain (γ 1 chain) of HuBA-1-3D-1. Amino acids are expressed in single-letter notation, and the position of the termination codon is indicated with “•” (black dot).

Figure 12 shows the nucleotide sequence (SEQ ID NO: 41) and amino acid sequence (SEQ ID NO: 42) of the coding region for the H chain (γ 1 chain) of HuBA-1-3D-2. Amino acids are expressed in single-letter notation, and the position of the termination codon is indicated with “•” (black dot).

Figure 13 shows the nucleotide sequence (SEQ ID NO: 69) and amino acid sequence (SEQ ID NO: 70) of the coding region for the L chain (κ chain). In the figure, amino acids are expressed in single-letter notation, and the position of the termination codon is indicated with “•” (black dot).

Figure 14 shows the nucleotide sequence (SEQ ID NO: 53) and amino acid sequence (SEQ ID NO: 54) of the coding region for the H chain (γ 1 chain) of HuBA-1-3D-1 T73K. Amino acids are expressed in single-letter notation, and the position of the termination codon is indicated with “•” (black dot). In the deduced VH amino acid sequence (SEQ ID NO: 18) of the above HuBA-1-3D-1 T73K, the N-terminal peptide of 19 amino acids is a signal peptide. The cDNA nucleotide sequence of a mature VH peptide of HuBA-1-3D-1 T73K is shown in SEQ ID NO: 19, and its deduced amino acid sequence is shown in SEQ ID NO: 20.

Figure 15 shows the nucleotide sequence (SEQ ID NO: 61) and amino acid sequence (SEQ ID NO: 62) of the coding region for the H chain (γ 1 chain) of HuBA-1-3D-1 A24G/T73K. Amino acids are expressed in single-letter notation, and the position of the termination codon is indicated with “•” (black dot). In the deduced VH amino acid sequence (SEQ ID NO: 22) of the above HuBA-1-3D-1 A24G/T73K, the N-terminal peptide of 19 amino acids is a signal peptide. The cDNA nucleotide sequence of a mature VH peptide of HuBA-1-3D-1 A24G/T73K is shown in SEQ ID NO: 23, and its deduced amino acid sequence is shown in SEQ ID NO: 24.

Figure 16 shows the amino acid sequence alignment of HuBA-1-3D-VH1, HuBA-1-3D-VH1 A24G, HuBA-1-3D-VH1 T73K, HuBA-1-3D-VH1 A24G/T73K, HuBA-1-3D-VH2, HuBA-1-3D-VH2 A24G, HuBA-1-3D-VH2 T73K and HuBA-1-3D-VH2 A24G/T73K, whose SEQ ID Nos in the Sequence Listing are given in parentheses.

Description of Embodiments

[0026] The present invention will be described in more detail below. The scope of the present invention is not limited by the following descriptions, and any embodiments other than those illustrated below may also be carried out with appropriate modifications without departing from the spirit of the invention. It should be noted that this specification incorporates the specification of Japanese Patent Application No. 2021-079977 (filed on May 10, 2021) in its entirety, based on which the present application claims priority. Moreover, all publications cited herein, including prior art documents, patent gazettes and other patent documents, are incorporated herein by reference.

As used herein, the term “glycosylation consensus sequence” is intended to mean an amino acid sequence represented by Asn-X-Ser/Thr (wherein X is an amino acid other than Pro), regardless of the position of this sequence in an antibody and the position where Asn is present. As used herein, the term “Fc region glycosylation consensus region” or “glycosylation consensus region” refers to a glycosylation consensus sequence usually comprising Asn297 present in the antibody Fc portion (typically, Asn297-X-Ser/Thr (wherein X is an amino acid other than Pro)). A nucleotide sequence encoding such a glycosylation consensus sequence or glycosylation consensus region includes any sequences as long as they each encode this amino acid sequence.

[0027] As used herein, the term “glycosylation isomers” is intended to mean antibodies having sugar chains attached to amino acids other than those in the glycosylation consensus region. Sugar chains attached to amino acids other than those in the glycosylation consensus region are referred to as “non-consensus sugar chains.” In glycosylation isomers, regions to which non-consensus sugar chains are linked include an Fab region, an antigen-binding Fv (variable) region, a complementarity determining region (CDR), an Fc region except for the glycosylation consensus region, and a fusion sequence portion in a fusion antibody, typically a CDR region. As to the sugar chain linkage mode of non-consensus sugar chains to amino acids other than those in the glycosylation consensus region, they may be N-linked sugar chains to the glycosylation consensus sequence Asn-X-Ser/Thr (wherein X is an amino acid other than Pro) or O-linked sugar chains to Ser or Thr.

[0028] The structure of an antibody molecule is generally a heterotetramer and is formed from two sets of two identical polypeptide chains joined together. Thus, linkage sites for non-consensus sugar chains are present at multiples of 2 per antibody molecule in theory. A crude antibody product to be purified in the present invention may contain antibodies having one or more non-consensus sugar chains. The number of non-consensus sugar chains linked per antibody molecule may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more. Moreover, since an antibody is composed of four polypeptide chains (usually two heavy chains and two light chains), the number of non-consensus sugar chains linked to any one of these polypeptide chains may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more,

6 or more, 7 or more, 8 or more, 9 or more, or 10 or more. The ratio of sugar chains linked to regions to which non-consensus sugar chains are linkable in a crude antibody product, i.e., the ratio of glycosylation isomers present in a crude antibody product may be 0.1% or more and 200% or less per antibody molecule, relative to the case where non-consensus sugar chains are completely linked to one of the “combinations of heavy and light chains” in one antibody molecule or a structure equivalent thereto, which is set to 100%. This ratio is usually 1% or more and 50% or less in a crude antibody product in need of applying the method of the present invention. 200% intended here means that non-consensus sugar chains are linked to both of the pairing “combinations of heavy and light chains” (i.e., two sites) in one antibody molecule.

[0029] As used herein, the term “antibody” includes not only a full-length antibody, but also an antibody fragment, and a fusion product of a full-length antibody or an antibody fragment with another substance. Examples include a mouse antibody, a mouse-human chimeric antibody, a humanized antibody, a human antibody, and their amino acid variants, addition variants, deletion variants, substitution variants and sugar chain variants, etc. The immunoglobulin class of an antibody is not limited in any way, and may be any of the immunoglobulin classes (isotypes) IgG, IgM, IgA, IgE, IgD and IgY, preferably IgG. Moreover, in the case of the IgG class, the antibody of the present invention may be of any subclass (IgG1, IgG2, IgG3 or IgG4). An antibody fragment is preferably an antigen-binding fragment, including F(ab')₂, Fab', Fab, Fab₃, single-chain Fv (hereinafter referred to as “scFv”), (tandem) bispecific single-chain Fv (sc(Fv)₂), single-chain triple body, nanobody, divalent V_HH, pentavalent V_HH, minibody, (double-chain) diabody, tandem diabody, bispecific tribody, bispecific bibody, dual affinity retargeting molecule (DART), tribody (or tribody), tetrabody (or [sc(Fv)₂]₂, or (scFv-SA)₄), disulfide-stabilized Fv (hereinafter referred to as “dsFv”), compact IgG, heavy chain antibody, or polymers thereof. A fusion product of an antibody fragment with another substance may be exemplified by a fusion protein, particularly an Fc fusion protein.

[0030] In particular, the antibody intended herein means an anti-hDLK-1 antibody whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or 12. It is preferably an anti-hDLK-1 antibody whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 4, 8, 16, 20, 24, 28, 32 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 12.

[0031] An antibody composition containing glycosylation isomers to be purified is herein referred to as a “crude antibody product.” Any crude antibody product may be used as long as it contains glycosylation isomers. Examples of a crude antibody product include a biological composition (e.g., plasma) or a treated product thereof, and a culture solution (which may be a culture supernatant; the same applies hereinafter) of antibody gene-transfected transformed cells or a treated product thereof. Such a biological composition may be exemplified by a composition comprising antibodies obtained from

a transgenic non-human animal or a plant, etc. Transformed cells are not limited in any way as long as they allow glycosylation, and specific examples include cell lines of animal, plant or yeast origin, which have the property of allowing glycosylation, and more specific examples include Chinese hamster ovary cells (CHO cells), mouse myeloma cells (NS0 cells, SP2/0 cells), rat myeloma cells (YB2/0 cells, IR983F cells), Syrian hamster kidney-derived BHK cells, human fetal kidney-derived 293 cells, human myeloma cells (Namalwa cells), embryonic stem cells, or antibody gene-transfected fertilized eggs, etc. As to the above cell lines, it is also possible to use various subspecies derived from primary immortalized cell lines. For example, in the case of CHO cells, it is possible to use CHO K1, CHO DG44 and CHO S cell lines, and their derived cell lines, etc. (Palsson et al., *Nature Biotechnology* 31(8), 759-765, 2013). When these cells are cultured in a medium suitable for protein production, a crude antibody product may be obtained as a culture solution. As to the medium used for this purpose, examples include a serum-containing medium, a medium containing no animal-derived component such as serum albumin or serum fraction, a serum-free medium and a protein-free medium, and preferred for use is a serum-free medium, a medium containing no animal-derived material, a protein-free medium, or a completely chemical synthetic medium.

[0032] Further, as to the above crude antibody product, it is also possible to use a biological composition or a culture solution treated by filtration, salting-out, one or more chromatography techniques, pH adjustment, buffer replacement, concentration, dilution, etc., or an intermediate composition derived from the biological composition or culture solution during purification or other operations. As an intermediate composition derived during purification, it is possible to use even a solution obtained after any unit operations required to construct the production process of antibody drugs. For example, it is desired to use a composition obtained after Protein A affinity chromatography, after cation exchange chromatography, after anion exchange chromatography, after buffer replacement, after low pH treatment, or after filtration, etc.

[0033] In the case of N-linked sugar chains, the possible presence of glycosylation isomers can be estimated from the amino acid sequence or gene sequence of the antibody. Moreover, regardless of the linkage mode of sugar chains, the positions for sugar chain linkages can be estimated by peptide mapping and mass spectrometry on the antibody. More conveniently, a peptide-N-glycosidase (PNGase)-treated antibody and a non-treated antibody may be compared by SDS polyacrylamide gel electrophoresis (SDS-PAGE), whereby sugar chain linkages can be observed as changes in protein electrophoretic bands.

[0034] Although the type of antibody is as shown above, this method is suitable as a purification method in the production of antibodies for use as antibody drugs including therapeutic, diagnostic or prophylactic antibodies. Antibody drugs are required to have a consistency in the content of antibody isomers contained therein, and are required to minimize product-related impurities (the ICH Q6B guideline). Examples of a therapeutic or prophylactic antibody include an antibody neutralizing the activity of a ligand through binding to the ligand, an antibody neutralizing the binding of a ligand

through binding to its receptor on the cell surface, and an antibody exerting cytotoxic activity on cells themselves through binding to their cell surface. Examples of a diagnostic antibody include an antibody binding to a ligand or a receptor on the cell surface. The cytotoxic activity on cells may be exemplified by antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis activity, etc. Moreover, the technique of the present invention may also be used for antibody derivatives as long as they have sugar chains, as exemplified by chemically modified antibodies (e.g., antibody-drug conjugates, radioisotope-labelled antibodies), fusion antibodies with cytokines, etc., and multi-specific antibodies (Nature, 580(16), 330-338 (2020)), etc.

[0035] In more detail, this method can be used in the purification of antibodies against protein antigens (preferably protein antigens of human origin), including CD3, EGF receptor, CD20, RS virus, TNF α , CD25, IL-6 receptor, CD33, VEGF, IgE, complement C5, IL-12, IL-23, IL-1 β , RANKL, CCR4, HER2, CD30, IL-5, IL-5 receptor, α 4 integrin, α 4 β 7 integrin, PD-1, CD52, IL-17, IL-17A, IL-17 receptor, CTLA-4, PCSK9, SLAMF7, BlyS, CD38, PD-L1, IL-4 α receptor, CD22, CD23, factor Ixa, factor X, CD19, sclerostin, DLK-1, etc. Examples of a fusion protein include a soluble TNF receptor Fc fusion protein, a CTLA4-modified Fc fusion protein, a Fc-TPOR agonist peptide fusion protein, a VEGF receptor-Fc fusion protein, etc. This method can be used in the purification of any of these antibodies or fusion proteins, etc.

[0036] One of the most desired cases is the purification of an anti-DLK-1 antibody. In more detail, it is a humanized anti-human DLK-1 antibody as appears in Patent Document 4 (WO2014/054820) given above, as exemplified by an antibody comprising a heavy chain having an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36 (particularly a heavy chain having any of these amino acid sequences as a variable region; the same applies hereinafter in this paragraph), and a light chain having the amino acid sequence shown in SEQ ID NO: 10 or 12 (particularly a light chain having any of these amino acid sequences as a variable region; the same applies hereinafter in this paragraph), and preferred is an antibody comprising a heavy chain having an amino acid sequence selected from SEQ ID NO: 4, 8, 16, 20, 24, 28, 32 and 36, and a light chain having the amino acid sequence shown in SEQ ID NO: 12. Such a humanized anti-human DLK-1 monoclonal antibody has a glycosylation consensus sequence in the variable region of its light chain.

[0037] Tables 1 and 2 below contain the full-length sequence of the anti-human DLK-1 antibody shown in Patent Document 4 (WO2014/054820) given above (each underlined section represents a signal sequence, and the underlined sequence is not contained in a mature protein). For example, in this antibody, N in the boxed NSS sequence serves as a glycosylation consensus sequence. For this reason, when animal cells or others are engineered to express this gene, there is a possibility that these cells will produce a sugar chain composition containing glycosylation isomers. Likewise, DLK-1 antibodies having sequences similar to the sequence of this anti-DLK-1 antibody also have the same

possibility. This method is useful as a method for removing or reducing glycosylation isomers from such a crude antibody product containing glycosylation isomers. It should be noted that the amino acid sequences of the H chain of HuBA-1-3D-1, the H chain of HuBA-1-3D-2, the H chain of HuBA-1-3D-1 A24G, the H chain of HuBA-1-3D-2 A24G, the H chain of HuBA-1-3D-1 T73K, the H chain of HuBA-1-3D-2 T73K, the H chain of HuBA-1-3D-1 A24G/T73K, the H chain of HuBA-1-3D-2 A24G/T73K, and the L chain of HuBA-1-3D given in the tables below are shown in SEQ ID Nos: 38, 42, 46, 50, 54, 58, 62, 66 and 70, respectively, in this order. Moreover, the amino acid sequences of mature proteins produced upon removal of signal sequences from the above sequences are shown in SEQ ID Nos: 40, 44, 48, 52, 56, 60, 64, 68 and 72, respectively, in this order. As used herein and elsewhere, the term “H chain” refers to a heavy chain, and the term “L chain” refers to a light chain.

[0038] In HuBA-1-3D VH1 and HuBA-1-3D VH2, the amino acid sequence of CDR1 is “DYAMH” (SEQ ID NO: 73), the amino acid sequence of CDR2 is “VISTYYGNTNYNQKFKG” (SEQ ID NO: 74), and the amino acid sequence of CDR3 is “GGLREYYYAMDY” (SEQ ID NO: 75). Likewise, in HuBA-1-3D VL, the amino acid sequence of CDR1 is “KSSQSLNSSNQKNYLA” (SEQ ID NO: 76), the amino acid sequence of CDR2 is “FASTRES” (SEQ ID NO: 77), and the amino acid sequence of CDR3 is “QQHYSTPPT” (SEQ ID NO: 78). The antibody of the present invention may be an antibody having all or some of these CDRs. It should be noted that these CDR sequences were according to the definition of Kabat et al. (Sequences of Proteins of Immunological Interests, Fifth edition, NIH Publication No.91-3242, U.S. Department of Health and Human Services, 1991). As used herein and elsewhere, the term “VH” refers to a heavy chain variable region, and the term “VL” refers to a light chain variable region.

[0039] [Table 1]

HuBA-1-3D-1 Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGKATMTVDSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-1-3D-1 A24G Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGKATMTVDSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-1-3D-1 T73K Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGKATMTVDKSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-1-3D-1 A24G/T73K Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGKATMTVDKSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVFPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

[0040] [Table 2]

HuBA-1-3D-2 Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGRATMTVDSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSEFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-1-3D-2 A24G Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGRATMTVDSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSEFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-1-3D-2 T73K Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGRATMTVDKSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSEFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-1-3D-2 A24G/T73K Heavy chain

MGWSCIIFFLVATATGVHSQVQLVQSGAEVKKPGASVKVSCKGSGYTFTDYAMHWVRQAP
GQGLEWIGVISTYYGNTNYNQKFKGRATMTVDKSTSTAYMELRSLRSDDTAVYYCARGGL
REYYYAMDYWGQGTMTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYITLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
LDSDGSEFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK

HuBA-VH1-3D LC Light chain

MESQTQVLMFLLLVWSGACADIVMTQSPDSLAVSLGERATINCKSSQSLLINSSINQKNYLA
WYQQKPGQPPKLLVYFASTRESGVDPDRFSGSGSGTDFTLTISLQAEDVAVYYCQQHYST
PPTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKDYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0041] An antibody composition whose glycosylation isomer content is reduced (herein referred to as a “purified antibody composition”) when compared to a crude antibody product can be obtained when the crude antibody product containing glycosylation isomers is used as a starting material and subjected to conventional chromatography. Accordingly, the present invention relates to a purification method for a crude antibody product, said method comprising: loading the crude antibody product on conventional chromatography to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media; and treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition, wherein the content of glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region in the resulting purified antibody composition is reduced when compared to the crude antibody product before being subjected to purification.

[0042] As a media for use in conventional chromatography, it is possible to use a hydrophobic interaction chromatography media, a hydrophobic chromatography media, or a mixed-mode chromatography media (also referred to as a multi-mode chromatography media, preferably a mixed-mode chromatography media having the nature of hydrophobic chromatography). For use as a hydrophobic interaction chromatography media, a base substrate may be attached with hydrophobic functional groups such as a methyl group, an ethyl group, a propyl group, a butyl group, an octyl group, a hexyl group, a propylene glycol group, a phenyl group, an alkylphenyl group, a benzyl group, and an alkylbenzyl group, etc. For use as a mixed-mode chromatography media, the above hydrophobic functional groups and ion-exchangeable functional groups may be mixed in any ratio. For example, N-benzyl-N-methylethanolamine and so on may be used as functional groups. Representative examples of cation-exchangeable functional groups include CM (carboxymethyl, $-O-CH_2-COOH$), SP (sulfopropyl, $-O-C_3H_6-SO_3H$) and so on, while representative examples of anion-exchangeable functional groups include DEAE (diethylaminoethyl, $-O-C_2H_4-N-(C_2H_5)_2$), QAE (quaternized aminoethyl or diethyl-(2-hydroxypropyl)-aminoethyl, $-O-C_2H_4-N-(C_2H_5)_2(CH_2-CH(OH)-CH_2)$) and so on, and these functional groups may be used. Examples of a substrate for the media include cellulose, Sephadex, crosslinked agarose, polyacrylamide, methacrylate and various synthetic polymers. The media may or may not be porous, and either may be used. Another form of a mixed-mode chromatography media may be exemplified by those having functional groups such as calcium phosphate, like hydroxyapatite ($Ca_{10}(PO_4)_6(OH)_2$) or fluoroapatite ($Ca_{10}(PO_4)_6F_2$).

[0043] A chromatography media may be obtained as a commercially available product and used. Specific examples include media such as Butyl-Sepharose[®] 4 Fast Flow (average particle size: 90 μm), Butyl-S Sepharose 6 Fast Flow (average particle size: 90 μm), Octyl Sepharose[®] 4 Fast Flow (average particle size: 90 μm), Phenyl Sepharose[®] 6 Fast Flow (high sub) (average particle size: 90 μm), Phenyl Sepharose[®] 6 Fast Flow (low

sub) (average particle size: 90 μm), Butyl Sepharose[®] High Performance (average particle size: 90 μm), Phenyl Sepharose High Performance (average particle size: 90 μm), SOURCE 15ETH (average particle size: 15 μm), SOURCE 15ISO (average particle size: 15 μm), SOURCE 15PHE (average particle size: 15 μm), Capto Phenyl (High Sub) (average particle size: 90 μm), Capto Butyl (average particle size: 90 μm), Capto Octyl (average particle size: 90 μm), Capto Phenyl ImpRes (average particle size: 36-44 μm), Capto Butyl ImpRes (average particle size: 36-44 μm), Capto adhere (average particle size: 90 μm), Capto adhere ImpRes (average particle size: 36-44 μm), Capto MMC (average particle size: 90 μm), Capto MMC ImpRes (average particle size: 36-44 μm), Capto Core 700 (average particle size: 90 μm), ReadyToProcess Adsorber Phenyl (which are all products of Cytiva, UK), TOYOPEARL[®] Butyl-600 (average particle size: 40-90 μm), TOYOPEARL[®] Phenyl-600 (average particle size: 40-90 μm), TOYOPEARL[®] PPG-600 (average particle size: 40-90 μm), TOYOPEARL[®] Butyl-650 (average particle size: 40-90 μm), TOYOPEARL[®] Phenyl-650 (average particle size: 40-90 μm), TOYOPEARL[®] SuperButyl-550 (average particle size: 40-90 μm), TOYOPEARL[®] Hexyl-650 (average particle size: 50-150 μm), TOYOPEARL[®] Ether-650 (average particle size: 40-90 μm) (which are all products of Tosoh Corporation, Japan), POROS Ethyl (average particle size: 50 μm), POROS Benzyl (average particle size: 50 μm), POROS Benzyl Ultra (average particle size: 50 μm) (which are all products of Thermo Fisher), Macro-Prep t-Butyl HIC (average particle size: 50 μm), Macro-Prep Methyl HIC (average particle size: 50 μm), ceramic hydroxyapatite (average particle size: 20-80 μm), ceramic fluoroapatite (average particle size: 20-80 μm), biogel HT (average particle size: 20-80 μm) (which are all products of Bio-Rad Laboratories, Inc), QMA Spherosil (average particle size: 50 μm), Methyl Ceramic Hyper D (average particle size: 50 μm) (which are all products of Pall Corporation), Fractogel EMD Phenyl (S) (average particle size: 20-90 μm), Fractogel EMD Propyl (S) (average particle size: 20-90 μm) (which are all products of Merck & Co., Inc.), Cellufine MAX Phenyl (average particle size: 40-130 μm), Cellufine MAX Phenyl LS (average particle size: 40-130 μm), Cellufine MAX Butyl (average particle size: 40-130 μm) (which are all products of JNC), butylated Chitopearl, phenylated Chitopearl (which are all products of Fujibo Holdings, Inc., Japan), etc. From among these media, a more suitable media is selected and used. More preferred are media such as Capto Butyl, POROS Benzyl Ultra, POROS Butyl Ultra, etc.

[0044] The average particle size of the chromatography media used for purification purposes in the present invention may be set to 15 μm or more, 20 μm or more, 30 μm or more, or 40 μm or more. Moreover, the volume of a crude antibody product which can be treated with the chromatography media may be set to 100 mL or more, 1 L or more, 10 L or more, or 100 L or more. As a chromatography column to be filled with this media, it is possible to use a chromatography column whose volume is 100 mL to around 1,000 L (diameter: 5 cm to around 2 m). The volume of a crude antibody product provided for chromatographic purification is at least 1 L or more, desirably 10 L or more, more desirably 100 L or more, even more desirably 500 L or more, and up to around

20,000 L. Due to the necessity to treat such a large volume of a crude antibody product, the linear flow rate in chromatography is 1,000 cm/hr or less, and desirably 500 cm/hr or less. The amount of antibody provided for purification is 10 g or more, desirably 100 g or more, more desirably 1 kg or more, and even more desirably 10 kg or more, calculated as the amount of protein. Glycosylation isomers to be removed or reduced by this technique are contained in the first half fraction of antibody eluted by chromatography, and the desired antibody of interest is eluted into the second half fraction, whereby the glycosylation isomers are fractionated and removed.

[0045] Conditions under which a crude antibody product containing glycosylation isomers is loaded on conventional chromatography should at least be sufficient to allow a component of interest, i.e., an antibody having a sugar chain attached only to the glycosylation consensus region (non-glycosylation isomer antibody) to be adsorbed to the chromatography media. Antibody adsorption is caused by interaction between the antibody and the chromatography media based on the degree of hydrophobicity-hydrophilicity. As a buffer, it is possible to use a buffer commonly used in hydrophobic interaction chromatography, hydrophobic chromatography, or mixed-mode chromatography. Any buffer may be used as long as the antibody is stable under chromatography conditions, and examples include phosphate buffer, acetate buffer, citrate buffer, Tris buffer, glycine buffer, borate buffer, tartrate buffer, MES buffer, HEPES buffer, MOPS buffer, amino acid buffer, and mixed buffers thereof. The concentration of these buffers may be selected freely within the commonly used range of around 0.1 mM to 300 mM. The buffer pH may be selected freely within the range of pH 4 to 8, but it is preferably pH 4 to 6.

[0046] To these buffers, a salt such as sodium sulfate, ammonium sulfate, sodium chloride or sodium citrate may optionally be added in an appropriate amount not to cause antibody precipitation, thereby enhancing antibody interaction with the above chromatography media and thus allowing antibody adsorption to the chromatography media. The above salt may be selected freely from one or more candidates. As to the salt concentration, antibodies are present stably in the range of 300 mM to 2 M salt, and the concentration used is required to allow sufficient antibody adsorption to the chromatography media. The salt concentration is preferably around 1 M, and a lower salt concentration allowing antibody adsorption is preferred for this purpose. The amount of antibody which can be adsorbed per unit amount of the chromatography media will widely vary depending on the type of the chromatography media and the conditions of the buffer, but 10 mg or more of antibody per mg of the media, preferably 20 mg or more of antibody per mg of the media can be adsorbed. The chromatography may be operated at any temperature in the range of 0°C to 40°C. The chromatography is desirably operated at room temperature, and more desirably operated under conditions where the temperature is controlled.

[0047] After the crude antibody product containing glycosylation isomers is loaded on chromatography under the conditions mentioned above, separation and purification are

conducted by elution. The separation of glycosylation isomers by chromatography may be accomplished as follows: after antibody adsorption to the chromatography media the buffer to be passed through the column is changed to reduce the salt concentration, increase the pH, reduce the conductivity, or combinations thereof, in a stepwise fashion, in a continuous fashion, or combinations thereof. After antibody adsorption to the chromatography media, glycosylation isomers may first be eluted as a major fraction, followed by eluting an antibody having a sugar chain attached only to the glycosylation consensus region (non-glycosylation isomer antibody) to thereby prepare a purified antibody composition of interest. The term "elution" means that an antibody component bound to a chromatography media through hydrophobic interaction, etc., is treated to weaken its binding to the media, and the antibody component is released from the chromatography media. The conditions required to elute glycosylation isomers are buffer conditions where the interaction between the glycosylation isomers and the chromatography media is sufficiently weaker than the interaction between the non-glycosylation isomer antibody and the chromatography media. When the chromatography media is washed with a sufficient volume of the buffer under these conditions, only the glycosylation isomers can be eluted and removed while ensuring that only the non-glycosylation isomer antibody, which is an antibody of interest, remains adsorbed to the chromatography media.

[0048] Any buffer may be used to elute and remove (wash) the glycosylation isomers, as long as it has a 10 mM or more difference in salt concentration and/or a 0.2 Unit or more difference in pH from the buffer used to elute the non-glycosylation isomer antibody. After the non-glycosylation isomer antibody is adsorbed to the chromatography media at a high salt concentration (usually within the range of 300 mM to 2 M), the salt concentration of the wash buffer used to wash the chromatography media may be set to be equal to or higher than the salt concentration for elution. For example, the salt concentration of the wash buffer may be equal to the salt concentration required for antibody elution or may range from equal to 1 M higher than the salt concentration required for antibody elution, or may range from equal to 0.5 M higher than the salt concentration required for antibody elution, or may be 10 mM or more higher than the salt concentration required for antibody elution, for example, may be set to 0.5 M or more or 1.0 M or more. The pH of the wash buffer may be set to be equal to or up to 2 Units higher than the pH for antibody adsorption, or may be set to be equal to or up to 2 Units lower than the pH for antibody elution. For example, the pH of the wash buffer may be 0.2 Units lower than the pH of the eluent. The pH of the wash buffer may be in the range of pH 4 to 8. Moreover, the passing volume of the buffer (wash buffer) required to elute and remove the glycosylation isomers may be set to 2 column volumes (CV) or more, 3 CV or more, 4 CV or more, 5 CV or more, 10 CV or more, 15 CV or more, or 20 CV or more, relative to the chromatography column volume, or may be set to 5 to 20 CV, 5 to 15 CV, 5 to 10 CV, or 10 to 20 CV, relative to the chromatography column volume.

[0049] During the process from loading to washing, the pH and/or salt concentration of

the crude antibody product may be changed in a stepwise fashion (e.g., one or more steps, two or more steps, three or more steps, several steps) or in a continuous fashion. The pH of the crude antibody product during the process from loading to washing is generally within the range of 4 to 6.

[0050] The conditions of the above salt concentration, pH and/or wash buffer volume may be determined as appropriate depending on the content of glycosylation isomers in the crude antibody product used as a starting material, and the properties of antibody per se including the isoelectric point and amino acid sequence, etc.

[0051] The chromatography-based method for separation of glycosylation isomers intended herein may comprise allowing the glycosylation isomers to flow through the chromatography media, and then eluting an antibody having a sugar chain attached only to the glycosylation consensus region, whereby a purified antibody composition containing the non-glycosylation isomer antibody with high purity can be prepared. The phrase “flow through” means that when a crude antibody product is loaded on a column filled with a chromatography media, glycosylation isomers are eluted out from the column without being adsorbed to the chromatography media. In this case, the glycosylation isomers in the crude antibody product may weakly interact with the chromatography media, but components containing these unwanted glycosylation isomers can be eliminated from the column by passing an equilibration buffer (desirably one or more column volumes) in a continuous or intermittent manner. As a buffer used to allow the glycosylation isomers to specifically flow through the column, a buffer is selected such that the interaction between the glycosylation isomers and the chromatography media is sufficiently weaker than the interaction between the antibody having a sugar chain linked only to the glycosylation consensus region and the chromatography media. When a sufficient volume of the buffer is used to allow only the glycosylation isomers to flow through from the chromatography media, only the antibody of interest can be adsorbed to the chromatography media. Then, a buffer whose salt concentration and other conditions differ from those of the above buffer is used to elute the bound antibody from the chromatography media, thereby preparing the desired purified antibody composition.

[0052] As a buffer used to allow only the glycosylation isomers to flow through the column, any buffer may be used as a wash buffer for flow through purposes as long as it has a 10 mM or more difference in salt concentration (i.e., a salt concentration of not less than 10 mM or higher) and/or a 0.2 Unit or more difference in pH (i.e., a pH of not less than 0.2 or lower) when compared to the eluent used to elute the antibody having a sugar chain linked only to the glycosylation consensus region. The salt concentration of the buffer may be set to be equal to or up to 1 M higher (preferably up to 0.5 M higher) than the salt concentration required to elute the non-glycosylation isomer antibody from the media. The salt concentration in this case is usually 100% or more relative to the salt concentration required for antibody elution. Alternatively, the column is washed with a wash buffer whose pH is equal to or up to 2 Units higher than the pH for antibody

adsorption or with a wash buffer whose pH is equal to or up to 2 Units lower than the pH for antibody elution. The pH or/and salt concentration may be changed in a single step or several steps, or may be changed in a continuous fashion. Moreover, the salt concentration or pH of the buffer is usually adjusted within an appropriate range before the crude antibody product serving as a starting material is applied onto the chromatography media. As to the passing volume of the buffer (wash buffer) required to allow the glycosylation isomers to flow through the column, conditions are selected such that the passing volume is twice or more, desirably 5 times or more of the volume of the chromatography media. The passing volume of the wash buffer is more desirably 10 to 20 times or more of the volume of the chromatography media. The above salt concentration, pH or/and wash buffer volume may be determined as appropriate depending on the content of glycosylation isomers in the crude antibody product used as a starting material.

[0053] Since the amount of antibody in the crude antibody product loaded on the chromatography media, i.e., the protein load on the chromatography media affects the resolution of glycosylation isomers, the protein load per unit volume of the chromatography media is determined so as to achieve the desired yield and purity (glycosylation isomer content) in the resulting purified antibody composition. In general, there is a limit on the amount of protein which can be adsorbed to the media during chromatography operation, so that the chromatography operation is controlled on the basis of parameters such as a maximum dynamic binding capacity (DBC). In general, a protein load below the maximum dynamic binding capacity provides good recovery and resolution of protein, and the desired separation effect of chromatography can be expected. Moreover, in the method of the present invention, a protein load above a certain amount is preferred to avoid the adsorption of unwanted glycosylation isomers, and protein is loaded in an amount which is at least 20 mg or more, 25 mg or more, 30 mg or more, or 35 mg or more, per unit amount (1 g) of the chromatography media or per unit volume (1 mL) of the chromatography media, and is equal to or less than the maximum dynamic binding capacity, whereby the glycosylation isomers are separated and removed. The protein load can be determined depending on the content of glycosylation isomers in the crude antibody product to be purified. Namely, if the content of glycosylation isomers is high in the crude antibody product before chromatographic purification, the protein load can be close to the maximum dynamic binding capacity.

[0054] In one aspect, the method of the present invention comprises the steps of selecting a conventional chromatography media to be used depending on the nature of antibody provided for separation, and optimizing the separation and removal of glycosylation isomers with the selected chromatography media.

[0055] The step of selecting a chromatography media may be accomplished as follows: a crude antibody product to be purified is first loaded on any two or more types of chromatography media under the above salt concentration and pH conditions to thereby

select a chromatography media which adsorbs more antibody having a sugar chain attached only to the glycosylation consensus region. Further, these chromatography media may optionally be eluted with an eluent whose salt concentration is reduced in a stepwise or continuous fashion, and eluents passing through the media are each measured for the levels of glycosylation isomers and/or an antibody having a sugar chain attached only to the glycosylation consensus region, whereby a chromatography media giving an eluent with reduced levels of glycosylation isomers and rich in the antibody having a sugar chain attached only to the glycosylation consensus region may be selected as a chromatography media which is more excellent in the separation of glycosylation isomers.

[0056] In the step of optimizing the separation and removal of glycosylation isomers with the selected chromatography media, conditions are considered and selected, including the composition, concentration and pH of a buffer used for loading, the type and concentration of a salt to be added, the amount of a crude antibody product loaded on the chromatography media, the composition, concentration and pH of a buffer used for washing, the frequency of washing and the volume of a wash buffer, the composition, concentration and pH of a buffer used for elution, the type and concentration of a salt to be added, and how to change them, and whether glycosylation isomers are removed by adsorption or flow through. In the optimization step of these conditions, individual parameters may be optimized one by one, or alternatively, statistical analysis procedures such as the design of experiments may be used to select the optimal conditions including interactions among several parameters.

[0057] Techniques for antibody purification involve various steps. Most processes for antibody purification are conducted in two or more steps using different chromatography modes, but purification processes are usually often constructed using three steps of chromatography. For example, two or more of Protein A affinity chromatography, cation exchange chromatography, anion exchange chromatography, mixed-mode chromatography, hydrophobic interaction chromatography and so on are used in combination. The method of the present invention may be integrated into any step of conventional chromatography in these antibody purification processes. In more detail, in a purification process comprising Protein A affinity chromatography in the first step, cation exchange chromatography in the second step and hydrophobic interaction chromatography in the third step, the method of the present invention may be used as hydrophobic interaction chromatography in the third step. Likewise, in the case of a purification process comprising Protein A affinity chromatography in the first step, mixed-mode chromatography in the second step and hydrophobic interaction chromatography in third step, the method of the present invention may be used as hydrophobic interaction chromatography in the third step. Likewise, in the case of a purification process comprising Protein A affinity chromatography in the first step, hydrophobic interaction chromatography in the second step and mixed-mode chromatography in the third step, the method of the present invention may be used as hydrophobic interaction chromatography in the second step. Further, in the case of a

purification process comprising Protein A affinity chromatography in the first step, anion exchange chromatography in the second step and hydrophobic interaction chromatography in third step, the method of the present invention may be used as hydrophobic interaction chromatography in the third step. Moreover, in the sequence of these chromatography steps, the method of the present invention may be used as a mixed-mode chromatography step in addition to hydrophobic interaction chromatography or in place of hydrophobic interaction chromatography.

[0058] The method of the present invention enables the efficient removal of glycosylation isomers and the provision of a purified antibody composition containing glycosylation isomers reduced to the desired content. By the method of the present invention, the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition after purification can be 10% or less, more desirably 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.5% or less, or 0.2% or less. Moreover, the ratio of glycosylation isomers relative to the total antibody in the crude antibody product before purification may be 50% or more, 20% or more, 10% or more, or 5% or more. The method of the present invention may be a method for obtaining an antibody with reduced content of glycosylation isomers in a step yield of 20% or more, 40% or more, or 50% or more.

[0059] The content and ratio of glycosylation isomers and the purification yield in the final purified antibody composition or the antibody composition after purification may be achieved by adjusting the above chromatography parameters. Preferably, these parameters are optimized such that glycosylation isomers are reduced to any levels and a purification yield acceptable for antibody production is obtained.

[0060] The status of glycosylation isomer removal may be confirmed by high-performance liquid chromatography (HPLC) or ultra-high performance liquid chromatography (UHPLC) for analysis and evaluation purposes. In these analyses, a media with an average particle size of 15 μm or less is used, and glycosylation isomers can be separated by chromatography at ultra-high flow rate and at ultra-high pressure. For example, columns suitable for this purpose include a TSKgel Butyl-NPR column (average particle size: 2.5 μm , Tosoh Corporation, Japan), a TSKgel Phenyl-5PR column (average particle size: 10 or 13 μm , Tosoh Corporation, Japan), a TSKgel Ether-5PW column (average particle size: 10 μm , Tosoh Corporation, Japan), a TSKgel BioAssist Phenyl column (average particle size: 10 μm , Tosoh Corporation, Japan), a Protein-Pak Hi Res HIC column (Waters), a BioPro HIC column (average particle size: 2.3 or 4 μm , YMC Co., Ltd., Japan), a Proteomix HIC column (average particle size: 1.7 or 5 μm , M&S Instruments Inc., Japan), an AdvanceBio HIC column (average particle size: 3.5 μm , Agilent), an MAbPac HIC-10 LC column (average particle size: 5 μm , Thermo Fisher), an MabPac HIC-20 LC column (average particle size: 5 μm , Thermo Fisher), an MabPac HIC-Butyl LC column (average particle size: 5 μm , Thermo Fisher), a Shim-pack Bio-HIC column (average particle size: 4 μm , Shimadzu Corporation, Japan), Shodex HIC PH-814 (average particle size: 10 μm , Shoko Co., Ltd., Japan), COSMOSIL

HIC (average particle size: 5 μ m, Nacalai Tesque Inc., Japan), etc.

[0061] The purified antibody composition thus purified by the method of the present invention can be used as an active ingredient of antibody drugs for use as therapeutic, prophylactic or diagnostic agents for various diseases in humans and animals.

Examples

[0062] The present invention will be further described in more detail by way of the following examples, which are not intended to limit the scope of the present invention.

Example 1

[0063] Preparation and compositional evaluation of crude antibody product (culture supernatant) containing antibodies having sugar chains linked to sites other than the glycosylation consensus region

The glycosylated antibody used was the humanized anti-human DLK-1 monoclonal antibody shown in WO2014/054820 having H and L chains (H chain: SEQ ID NO: 64, L chain: SEQ ID NO: 72 in the present application) (hereinafter referred to as “anti-hDLK-1 antibody”). This antibody has a glycosylation consensus sequence in the variable region of its light chain. For this reason, when animal cells or others are engineered to express this gene, there is a possibility that these cells will produce a sugar chain composition containing glycosylation isomers as a contaminant.

[0064] The CHO cell line DG44 was transformed with an expression vector carrying a gene encoding the amino acid sequence of the anti-hDLK-1 antibody to prepare a stable expression cell line pool, DGC8-R-T11-14.2d. This cell line pool was used and cultured in a DASGIP® Parallel Bioreactor System (Eppendorf) bioreactor on a 1 L scale. The culture was conducted using a serum-free completely chemical synthetic medium by the fed-batch mode for 13 days under conditions of pH 7 and 34°C to 37°C. This culture supernatant was purified by Protein A chromatography (with a MabSelect SuRe media (Cytiva)) to obtain an antibody composition.

[0065] <HIC-HPLC analysis of antibody composition>

The resulting antibody composition was subjected to HIC-HPLC analysis under the following conditions.

HPLC apparatus: a Prominence HPLC System (Shimadzu Corporation, Japan)

Analytical column: a TSKgel Butyl-NPR column (Tosoh Corporation, Japan, 0014947; 4.6 mm $\times$ 3.5 cm, average particle size: 2.5 μ m)

Mobile phase A: 0.1 M sodium phosphate buffer (pH 7.0) containing 2.3 M ammonium sulfate

Mobile phase B: 0.1 M sodium phosphate buffer (pH 7.0)

Analysis conditions: injected at a protein concentration of 2 mg/mL $\times$ 10 μ L, gradient: 0 to 3 minutes; 0% B, 3 to 15 minutes; 0% to 100% B, 15 to 20 minutes; 100% B, flow rate: 0.5 mL/min, detection wavelength: 220 nm or 280 nm

[0066] As shown in Figure 1, three peaks were separated, i.e., a main peak (Peak 3) was detected at an elution time of around 13 minutes, and Peak 2 and Peak 1 were detected at

elution times of around 12.5 minutes and 12.0 minutes, respectively. Peak 3 was an antibody having a sugar chain linked only to the glycosylation consensus region, while Peak 2 was deemed to be a glycosylation isomer having additional one sugar chain linked to the antibody of Peak 3, and Peak 1 was deemed to be a glycosylation isomer having additional two sugar chains linked to the antibody of Peak 3 (see Example 2). This analysis result indicates that the crude antibody product obtained by culturing cells of the above pool was confirmed to contain about 10% of glycosylation isomers.

Example 2

[0067] Preparation and glycosylation status confirmation of crude antibody product (culture supernatant) containing antibodies having sugar chains linked to sites other than the glycosylation consensus region

An expression vector (pFUSE) carrying gene sequences encoding the amino acid sequences of the heavy and light chains of the anti-hDLK-1 antibody, and an expression vector (pFUSE) encoding a mutant sequence (Asn-Ser-Ala) comprising a point mutation introduced into the third amino acid in the glycosylation consensus sequence (Asn-Ser-Ser) in the light chain of the anti-hDLK-1 antibody and encoding the amino acid sequence of the heavy chain of the anti-hDLK-1 antibody were each used to transform ExpiCHO cells to cause the transient expression of each antibody protein. Their culture supernatants were purified by Protein A affinity chromatography, and the resulting crude antibody products were treated with peptide-N-glycosidase F (PNGase F) or not treated with PNGase F, and then analyzed by reducing SDS polyacrylamide gel electrophoresis (SDS-PAGE) (silver staining). The unmutated anti-hDLK-1 antibody is designated as NSS antibody, while the anti-hDLK-1 antibody whose light chain glycosylation consensus sequence was mutated is designated as NSA antibody.

[0068] As a result, as shown in Figure 2, in the NSS antibody, a band with a molecular weight of greater than 25 kDa was found above the 25 kDa light chain band under non-PNGase F-treated conditions, but this band disappeared upon PNGase F treatment. This means that the NSS antibody was confirmed to have a sugar chain linked to the light chain having a consensus sequence other than the glycosylation consensus region in the antibody. On the other hand, this band was not found in NSA, regardless of the presence or absence of PNGase F treatment. These results indicate that a transient expression-derived crude product of the humanized anti-DLK-1 monoclonal antibody (NSS antibody) contains glycosylation isomers having sugar chains attached to the light chain.

Example 3

[0069] Separation of glycosylation isomers with hydrophobic interaction chromatography media (1)

A culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers.

To this crude antibody product, sodium chloride was added to give a final concentration of 1.0 M, and the crude antibody product was then adjusted to pH 5.0 and provided for use as a loading sample on a chromatography media.

[0070] Using this crude antibody product, its adsorption properties to a hydrophobic interaction chromatography column (column volume: 5 mL) filled with Capto Butyl (average particle size: 90 µm, Cytiva) were evaluated in bind-elute mode. The amount of the sample loaded on the column was set to 15 mg/mL as the protein load per unit volume of the media, and the flow rate was set to 300 cm/h. The chromatography was conducted under the following mobile phase conditions.

Mobile phase A: 20 mM sodium citrate-15 mM Tris buffer (pH 5.0) containing 1 M sodium chloride

Mobile phase B: 20 mM sodium citrate-15 mM Tris buffer (pH 5.0)

1. Equilibration: 100% mobile phase A; 10 column volumes (CV)
2. Loading: sample of the crude antibody product
3. Washing: 100% mobile phase A; 10 CV
4. Linear gradient elution: from 0% mobile phase B to 100% mobile phase B in 40 CV
5. Column washing: 1 M sodium hydroxide; 5 CV

[0071] Figure 3 shows an elution chromatogram (HIC 389). This result is indicative of antibody component adsorption to the Capto Butyl media under linear gradient conditions. The loading sample on the column, the flow-through fraction from the Capto Butyl column, and the adsorption fraction to the same column were evaluated by HIC-HPLC analysis as shown in Example 1. The results obtained are shown in Figure 4. Glycosylation isomers contained at 2.1% (Peak 1) and 12.1% (Peak 2) in the loading sample were removed into the flow-through fraction (HIC 389 Flow-through), and a glycosylation isomer-free antibody composition of 100% purity (antibody having no sugar chains attached to sites other than the glycosylation consensus region) (Peak 3) was obtained in the column adsorption fraction (HIC 389 Elute).

[0072] These results indicate that glycosylation isomers can be separated by using a hydrophobic interaction chromatography media (Capto Butyl). It is indicated that upon use of the selected chromatography media, glycosylation isomers are efficiently removed into the flow-through fraction, and a high-purity purified antibody composition is obtained in the adsorption fraction.

Example 4

[0073] Separation of glycosylation isomers with hydrophobic interaction chromatography media (2)

A culture supernatant containing the humanized anti-human DLK-1 monoclonal antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers. To this crude antibody product, sodium chloride was added to

give a final concentration of 1.0 M, and the crude antibody product was then adjusted to have a pH of 4.5, 4.7 or 5.0 and a conductivity of 70 mS/cm or less and provided for use as a loading sample on a chromatography media.

[0074] Using this crude antibody product, its adsorption properties to a hydrophobic interaction chromatography column (column volume: 5 mL) filled with Capto Butyl (average particle size: 90 μ m, Cytiva) or POROS Benzyl Ultra (average particle size: 50 μ m, Thermo Fisher) were evaluated in bind-elute mode. The amount of the protein sample loaded on each column was set to 20 mg/mL as the protein load per unit volume of the media, and the flow rate was set to 300 cm/h. The chromatography was conducted under the following mobile phase conditions.

Mobile phase A: 20 mM sodium citrate buffer (pH 4.5, 4.7 or 5.0) containing 1 M sodium chloride

Mobile phase B: 20 mM sodium citrate buffer (pH 4.5, 4.7 or 5.0)

1. Equilibration: 100% mobile phase A; 5 CV
2. Loading: sample solution
3. Washing: 100% mobile phase A; 8 CV
4. Washing 1: 100% mobile phase A; 5 CV
5. Washing 2: 100% mobile phase B + 0.8 M sodium chloride; 5 CV
6. Elution: 100% mobile phase B; 10 CV
7. Column washing: water (q.s.)
8. Column washing: 1 M sodium hydroxide (q.s.)

[0075] Elution chromatograms from Capto Butyl and POROS Benzyl Ultra are shown in Figure 5A and Figure 5B, respectively. Under all pH conditions, the antibody composition was able to be adsorbed to the Capto Butyl media and then eluted. Good adsorption and elution were also observed for POROS Benzyl Ultra. In more detail, in the graphs shown in Figure 5A and Figure 5B, peaks appearing around 0 to 50 mL in the horizontal axis are antibodies (glycosylation isomers) which were eluted by flowing through the column without being adsorbed, while an antibody eluted as a peak ranging from 50 to 300 mL indicates that an antibody having no sugar chains attached to sites other than the glycosylation consensus region is gradually eluted from the column. In the case of Capto Butyl, antibody elution was observed throughout washing/elution, regardless of pH, thus indicating that the antibody having no sugar chains attached to sites other than the glycosylation consensus region can be obtained with high purity when collecting an intermediate layer of elution. In the case of Poros Benzyl Ultra, the peak was found to vary depending on pH (at pH 4.5, the antibody was well adsorbed and eluted from the column during the second half of elution, whereas at pH 5.0, around 80% of the antibody was not adsorbed, and the antibody was eluted during washing), thus indicating that the component to be eluted can be controlled depending on pH. These results indicate that glycosylation isomers can be separated by using either Capto Butyl or POROS Benzyl Ultra, thus suggesting that separation of glycosylation isomers is possible with a hydrophobic interaction chromatography media. Moreover, this result indicates

that hydrophobic interaction chromatography allows the adsorption of an antibody composition and achieves the removal of glycosylation isomers when optimizing the pH, salt concentration and volume of a wash buffer/eluent.

Example 5

[0076] Study on the removal efficiency of glycosylation isomers (purity and yield) in hydrophobic interaction chromatography media, depending on the salt concentration for loading, the salt concentration and pH for washing, and the type of elution buffer.

The Capto Butyl and POROS Benzyl Ultra chromatography media were studied as to whether they were able to remove glycosylation isomers by stepwise elution. For use as a loading solution, the crude antibody product of Example 1 purified by Protein A affinity chromatography was adjusted with 0.5 M Tris to pH 4.5 or pH 5.0. As parameters, the salt concentration of a sample loading solution, the pH and salt concentration of wash buffers (wash buffer I, wash buffer II), and the type and pH of an elution buffer were studied to measure the yield of antibody and the purity of non-glycosylation isomer antibody in the purified fraction (i.e., the purity of antibody having no sugar chains attached to sites other than the glycosylation consensus region) (the content of glycosylation isomers by HIC-HPLC analysis). The test results obtained are shown in Table 3.

[0077] [Table 3]

Evaluation design and buffers for the hydrophobic interaction chromatography scouting.

Column	Load [M NaCl]	Load [pH]	Wash I [M NaCl]	Wash I [pH]	Wash II [M NaCl]	Wash II [pH]	Wash II [buffer]	Elution [pH]	Elution [buffer]	Yield [%]	Purity Analytical HIC [%]
Capto Butyl	1	4.5	1	4.5	1	4.5	Na-citrate	5	Na-citrate	73	97.1
	1	4.5	1	5	0.8	6	Histidine	6	Histidine	68	98.9
	1	4.5	1	4.5	1	4.5	Na-citrate	5	Na-citrate	63	99.1
	1	4.5	1	5	1	5	Na-citrate	6	Na-citrate	60	99.1
	1	4.5	1	4.5	0.8	5	Na-citrate	5	Na-citrate	59	98.9
	1	4.5	1	5	0.8	5	Na-citrate	5	Na-citrate	56	99.3
	1	4.5	1	4.5	1	5	Na-citrate	6	Histidine	41	95.1
	1	4.5	1	6	1	6	Na-citrate	6	Na-citrate	36	99.3
	1	4.5	1	4.5	1	4.5	Na-citrate	6	Histidine	23	100
	0.8	5	0.8	5	0.6	5	Na-citrate	6	Na-citrate	67	100
Poros Benzyl Ultra	0.6	5	0.6	5	0.6	5	Na-citrate	6	Na-citrate	59	100
	0.6	5	0.6	5	0.6	5	Na-citrate	6	NaPP	54	100
	0.6	5	0.6	5	0.6	5	Na-citrate	6	Histidine	48	100
	0.6	5	0.6	5	0.55	5	Na-citrate	6	Na-citrate	47	100
	0.6	5	0.6	5	0.55	5	Na-citrate	6	Na-citrate	46	100
	0.7	5	0.7	5	0.6	5	Na-citrate	6	Na-citrate	40	100
	0.6	5	0.6	5	0.6	5	Na-citrate	6	Na-citrate	39	100
	0.55	5	0.55	5	0.55	5	Na-citrate	7	Histidine	33	100
	0.9	5	0.9	5	0.6	5	Na-citrate	6	Na-citrate	39	n/a

[0078] The purification yield with the Capto Butyl media under the respective conditions was 23% to 73%, and the purity of the purified antibody composition (antibody component free from glycosylation isomers) by HIC-HPLC analysis was 97.1% to 99.3%. On the other hand, the purification yield with the POROS Benzyl Ultra media was slightly lower (33% to 67%), but the purity of the purified antibody composition by HIC-HPLC analysis was 100% under all the conditions. In particular, among the conditions used to study the POROS Benzyl Ultra media, conditions where a sample containing 0.8 M sodium chloride was loaded, and the media was washed sequentially with wash buffer I containing 0.8 M sodium chloride and then wash buffer II containing 0.6 M sodium chloride, and eluted with sodium citrate buffer of pH 6 were found to be optimal in terms of purity and yield.

[0079] Moreover, the results of this series of tests indicate the following.

- (i) The purity is improved with increase in the pH of the wash buffer (wash buffer I and/or wash buffer II).
- (ii) The yield is reduced with increase in the pH of the wash buffer (wash buffer I and/or wash buffer II).
- (iii) The purity is improved with increase in the pH of the eluent.
- (iv) The yield is reduced with increase in the pH of the eluent.
- (v) The yield is reduced with decrease in the salt concentration of the loading solution and/or the wash buffer.
- (vi) The conditions can be set to achieve 95% or more, ideally 99% or more purity of the antibody composition.

[0080] As can be seen from these results, it is indicated that the yield and the amount of glycosylation isomer contamination can be optimized in hydrophobic interaction chromatography media (e.g., Capto Butyl and POROS Benzyl Ultra) when optimizing the salt concentration and pH of a loading solution, the salt concentration and pH of a wash buffer, the volume of the wash buffer, the frequency of washing, the pH for elution and the type of buffer.

Example 6

[0081] Optimization of washing conditions for controlling the rate of glycosylation isomer contamination and the purity and yield of desired product

A culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers. To this crude antibody product, sodium chloride was added to give a final concentration of 1.0 M, and the crude antibody product was then adjusted as appropriate for its pH and conductivity and provided for use as a loading sample on a chromatography media. Using this crude antibody product and the POROS Benzyl Ultra media, the load mass of the sample and the volumes of wash buffer I and wash buffer II were used as input parameters to evaluate the yield and the purity by HIC-HPLC analysis, which were output

parameters.

[0082] As a result, it was indicated that the yield was able to be controlled to 40% to 80% with 97% to 100% purity when the protein load per unit volume of the chromatography media was adjusted to 25 g/L or more, and wash buffer I and wash buffer II were adjusted to 5 to 15 column volumes (CV) (Table 4). In particular, the purity of the resulting purified antibody composition tended to be higher when the protein load was 30 g/L or 35 g/L than when the protein load was 25 g/L. Moreover, when increasing the volume of each wash buffer, there was a tendency that the yield of the resulting purified antibody composition was reduced, but its purity was improved. This result indicates that under low protein load conditions, the purity of the purified antibody composition can be increased by increasing the volume of each wash buffer.

Namely, this result indicates that when the protein load in chromatography is set to a certain value or higher and/or when the volume of each wash buffer is controlled appropriately, the content of glycosylation isomers can be reduced and controlled from about 10% to the range of 3% to 0%. These results were analyzed by the design of experiment (DoE), and the results obtained are shown in Figure 6. The volumes of wash buffer I and wash buffer II and their effect on the yield and purity are expressed in contour chart form, thus indicating that any yield and purity can be controlled by the volumes of wash buffers.

[0083] [Table 4]

Evaluation design and buffers for the hydrophobic interaction chromatography scouting with Poros Benzyl Ultra.

Run	Run ID	Load Mass [g/L]	Flow rate [cm/h]	Wash I [CV]	Wash II [CV]	Yield [%]	Purity [analytical HIC]
1	HIC 464 001	25	300	10	7.5	73.0	98.4
2	HIC 464 002	30	300	10	5	64.0	99.6
3	HIC 464 003	25	300	15	10	65.4	99.6
4	HIC 464 004	35	300	15	5	50.0	100
5	HIC 464 005	35	300	10	7.5	49.4	100
6	HIC 464 006	25	300	15	5	69.4	99.1
7	HIC 464 007	30	300	5	7.5	62.7	99.6
8	HIC 464 008*	30	300	10	7.5	59.5	100
9	HIC 464 009*	30	300	10	7.5	58.5	100
10	HIC 464 010	30	300	15	7.5	54.8	100
11	HIC 464 011	35	300	5	5	57.1	100
12	HIC 464 012	35	300	15	10	44.4	100
13	HIC 464 013	30	300	10	10	56.1	100
14	HIC 464 014*	30	300	10	7.5	58.2	100
15	HIC 464 015	35	300	5	10	48.7	100
16	HIC 464 016	25	300	5	5	74.0	97.1
17	HIC 464 017	25	300	5	10	66.1	99.0
18	HIC 467 001	40	200	15	5	40.4	n/a
19	HIC 467 002	35	200	15	5	46.2	n/a

* triplicate run

Example 7

[0084] Position of glycosylation isomer removal step in purification process and effect of wash buffer volume on purity

A culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers. This crude antibody product was kept at pH 3 to 4 for a certain period of time and neutralized for use as a loading sample on a chromatography media.

[0085] This crude antibody product was purified through the two flows shown in Figure 7, i.e., purified sequentially by hydrophobic interaction chromatography and then mixed-mode chromatography, or sequentially by mixed-mode chromatography and then

hydrophobic interaction chromatography. The media used in hydrophobic interaction chromatography was POROS Benzyl Ultra, and the media used in mixed-mode chromatography was Capto MMC. The conditions used for hydrophobic interaction chromatography are as shown below. For ID Nos. HIC 446, HIC 457 and HIC 463, hydrophobic chromatography was followed by mixed-mode chromatography. For ID No. HIC 447, mixed-mode chromatography was followed by hydrophobic chromatography.

[0086] <Conditions for hydrophobic interaction chromatography>

Media: POROS Benzyl Ultra

Column size: 260 mL, bed height: 13.3 cm

Flow rate: 300 cm/h

Protein load per unit volume of the media: 30 g/L

Chromatography conditions:

1. Equilibration: 20 mM sodium citrate (pH 5.0) containing 0.8 M sodium chloride; 5 CV
2. Loading: sample of the crude antibody product
3. Washing 1: 20 mM sodium citrate (pH 5.0) containing 0.8 M sodium chloride; 6 CV (HIC 446/HIC 447), 8 CV (HIC 457) or 15 CV (HIC 463)
4. Washing 2: 20 mM sodium citrate (pH 5.0) containing 0.6 M sodium chloride; 5 CV
5. Elution: 20 mM sodium citrate (pH 6.0); 6.3 CV
6. Column washing: 1 M aqueous sodium hydroxide; 3 CV

[0087] The yield and purity of the purified antibody compositions obtained in the step of hydrophobic interaction chromatography are shown in Table 5 and Figure 8. In either purification flow, the yield was 60% or more, and the purity by HIC-HPLC analysis (which represents the amount of glycosylation isomer contamination) was 99% or more. Moreover, it was indicated that the yield and purity were able to be controlled depending on the volume used in Washing 1 (6 to 15 CV). Namely, the composition with about 90% antibody purity was found to improve its purity to around 98% when washed with 5 CV, around 99% when washed with 8 CV, and around 99.5% when washed with 15 CV.

[0088] [Table 5]

Results of the scale-up run of the HIC chromatography.

Run	Load amount		Yield		Monomer content	Purity analytical HIC
ID no.	[g/L Resin] acc. UV280	[g] acc. UV280	[g] acc. UV280	[%] acc. UV280	[%] acc. SEC-HPLC	[%] acc. HIC
HIC 446	30	7800	6113	78	99.7	97.6
HIC 447	30	7917	5671	72	99.8	98.3
HIC 457	30	7834	5650	72	99.7	98.7
HIC 463	30	7834	4923	63	99.8	99.6

Example 8

[0089] Purification process including glycosylation isomer removal step (POROS Benzyl Ultra)

A culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was obtained in a volume of about 200 L. The crude antibody product was confirmed to contain about 10% of glycosylation isomers.

[0090] The culture supernatant was filtered and then subjected to Protein A affinity chromatography (MabSelect SuRe 10 L; Cytiva), low pH viral inactivation, hydrophobic interaction chromatography with a POROS Benzyl Ultra media (Thermo Fisher, 10 L), mixed-mode chromatography with a Capto adhere media (Cytiva, 10 L), viral filtration, replacement with formulation buffer by tangential flow filtration (TFF), sterile filtration and other steps to obtain a high-purity purified antibody composition.

[0091] For POROS Benzyl Ultra chromatography, the protein load per unit volume of the media was adjusted to 35 g/L, 30 g/L and 16 g/L, and three chromatography runs were conducted. The conditions used for the POROS Benzyl Ultra chromatography step, and the results of the POROS Benzyl Ultra chromatography step are shown in Table 6 and Table 7, respectively.

[0092] [Table 6]

Parameter	Conditions
Column	Media volume: 10 L, bed height: 20 cm
Equilibration	20 mM sodium citrate buffer (pH 5.0) containing 0.8 M sodium chloride, 4 CV
Loading solution	Protein concentration: 6.71 mg/mL (total volume: about 125 kg, total protein: 841 g)
Load per unit volume of media	Load: 35 g/L-resin (loading volume: about 52 L), 30 g/L-resin (loading volume: about 45 L), 16 g/L-resin (loading volume: about 24 L)
Washing 1	20 mM sodium citrate buffer (pH 5.0) containing 0.8 M sodium chloride, 15 CV
Washing 2	20 mM sodium citrate buffer (pH 5.0) containing 0.6 M sodium chloride, 5 CV
Elution	20 mM sodium citrate buffer (pH 6.0), 10 CV
Washing 3	1 M aqueous sodium hydroxide

[0093] [Table 7]

	Run 1	Run 2	Run 3
Load	35 g/L	30 g/L	16 g/L
Yield	54%	58%	77%
Purity	100%	100%	89.74%

[0094] The loads in Run 1 and Run 2 were each in an appropriate range above the predetermined amount, whereas the load in Run 3 was as low as 16 g/L. As a result, the yield in Run 3 was 77%, but a low value of 89.74% was obtained for HIC-HPLC purity, which represents the amount of glycosylation isomer contamination. Thus, only the fractions from Run 1 and Run 2 were combined and provided for the subsequent chromatography step.

[0095] The purified antibody composition finally obtained through all the steps was obtained with a total yield of 46%. Moreover, the purity of the purified antibody composition by HIC-HPLC analysis was 100%, thus indicating that the purified antibody composition contained no glycosylation isomers. In this way, a purified antibody composition with sufficiently reduced levels of glycosylation isomers was able to be obtained even under chromatography conditions for antibody. Moreover, the protein load on the chromatography media was also shown to be important in the removal rate of glycosylation isomers.

Example 9

[0096] Purification process including glycosylation isomer removal step (Capto Butyl)

A culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was obtained. The crude antibody product was confirmed to contain about 10% of glycosylation isomers.

[0097] This culture solution was used and purified through the following steps in this order: Protein A affinity chromatography (media: MabSelect SuRe), low pH viral inactivation, hydrophobic interaction chromatography (Capto Butyl media) and mixed-mode chromatography (Capto adhere).

[0098] As can be seen from the results shown in Table 8, the rate free from glycosylation isomers was able to be improved to a purity of 99.8% by the hydrophobic chromatography step, thus obtaining the purified antibody composition with a total yield of 25%.

As indicated in this result, it is shown that a highly purified antibody composition can also be obtained even when using any hydrophobic interaction chromatography media other than the POROS Benzyl Ultra media.

[0099] [Table 8]

Purification step	Yield	Purity	Conditions, etc.
Culture supernatant	100%	90%	-
Protein A affinity chromatography	>90%	89.9%	-
Low pH	100%	89.9%	-
Hydrophobic interaction chromatography (Capto Butyl media)	37%	99.8%	Load: 20 mg/mL, washed with 30 CV of 20 mM sodium citrate buffer (pH 4.5) containing 0.8 M sodium chloride, and then eluted with 10 CV of 20 mM sodium citrate buffer (pH 4.5) containing 50 mM sodium chloride and 75 mM arginine hydrochloride
Mixed-mode chromatography (Capto adhere media)	>90%	99.8%	-
Total purification process	25%	99.8%	-

Example 10

[0100] Fractionation of glycosylation isomers and measurement of their biological activity

A crude anti-hDLK-1 antibody product containing about 10% of glycosylation isomers obtained in the same manner as shown in Example 1 was precisely fractionated into individual peaks using the HIC-HPLC analysis system shown in Example 1. The fractionation was accomplished in about ten times, and fractions were combined for each peak, followed by buffer replacement with isotonic phosphate buffer. It should be noted that the HIC-HPLC mobile phase conditions used for fractionation were changed as shown below.

Mobile phase A: 50 mM phosphate buffer (pH 7) containing 2.3 M ammonium sulfate

Mobile phase B: 50 mM phosphate buffer (pH 7)

[0101] The crude antibody product before fractionation (a) and the purified antibody composition after fractionation (b, c) were analyzed by the HIC-HPLC system shown in Example 1, and the results obtained are shown in Figure 9.

[0102] These samples were diluted at a 3-fold common ratio starting from 10 µg/mL, and measured for ADCC activity with an ADCC Reporter Bioassay kit (Promega, G7010) under conditions where the E:T ratio was 6:1 (target cell: HEK293 cell line highly expressing DLK1) and the reaction time was 6 hours. The results obtained are shown

in Figure 10. The crude antibody product before fractionation and the main peak after fractionation ((b) in Figure 9) showed substantially the same sigmoid curve, and were confirmed to have equal biological activity. In contrast, the glycosylation isomers isolated by fractionation ((c) in Figure 9) showed almost no signal at all the concentrations tested, and were found to have no biological activity. This result confirms that glycosylation isomers are impurities and are components which should be removed as much as possible as ingredients of biopharmaceuticals.

Industrial Applicability

[0103] The present invention enables the preparation and use of a purified antibody composition with reduced levels of glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region.

CLAIMS

[Claim 1]

A purification method for an anti-hDLK-1 antibody composition, whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, said method comprising:

Loading a crude antibody product on conventional chromatography to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to a media of the chromatography; and

treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition,

wherein the content of glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region in the resulting purified antibody composition is reduced when compared to the crude antibody product.

[Claim 2]

The purification method according to claim 1, wherein the media of the conventional chromatography is a hydrophobic interaction chromatography media or a mixed-mode chromatography media.

[Claim 3]

The purification method according to claim 1 or 2, wherein the media of the conventional chromatography has an average particle size of 15 μm or more.

[Claim 4]

The purification method according to claim 1 or 2, wherein the media of the conventional chromatography has an average particle size of 20 to 100 μm .

[Claim 5]

The purification method according to any one of claims 1 to 4, wherein the media of the conventional chromatography has a benzyl group or a butyl group.

[Claim 6]

The purification method according to any one of claims 1 to 5, wherein the protein load per unit volume of the media of the conventional chromatography is 20 mg/mL or more.

[Claim 7]

The purification method according to any one of claims 1 to 6, wherein the media of the conventional chromatography is a hydrophobic interaction chromatography media, and wherein said method comprises, after loading the crude antibody product on the media, washing the media with a wash buffer before elution.

[Claim 8]

The purification method according to claim 7, characterized in that the salt concentration of the wash buffer is 10 mM or more higher than the salt concentration of the eluent.

[Claim 9]

The purification method according to claim 7 or 8, characterized in that the salt concentration of the wash buffer is 0.5 M or more.

[Claim 10]

The purification method according to claim 7 or 8, characterized in that the salt concentration of the wash buffer is 1.0 M or more.

[Claim 11]

The purification method according to any one of claims 7 to 10, wherein the pH of the wash buffer is 0.2 Units or more lower than the pH of the eluent and is within the range of pH 4 to 8.

[Claim 12]

The purification method according to any one of claims 7 to 11, wherein the washing is accomplished by passing two or more column volumes of the wash buffer.

[Claim 13]

The purification method according to any one of claims 7 to 12, characterized in that the washing and elution are accomplished by using a mobile phase whose pH or/and salt concentration change in a stepwise or linear fashion.

[Claim 14]

The purification method according to any one of claims 7 to 13, wherein the eluent has a salt concentration of 0.5 M or less or contains no salt and has a pH of 5 to 7.

[Claim 15]

The purification method according to any one of claims 1 to 14, wherein said method gives a yield of 20% or more.

[Claim 16]

The purification method according to any one of claims 1 to 15, wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is 5% or less.

[Claim 17]

The purification method according to claim 16, wherein the ratio of glycosylation isomers relative to the total antibody in the crude antibody product is higher than 5%.

[Claim 18]

The purification method for an anti-hDLK-1 antibody composition according to claim 1, said method comprising:

loading the crude antibody product on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm ;

allowing the antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media;

washing the media one or more times with a wash buffer of pH 4 to 6 to remove glycosylation isomers; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a

salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

[Claim 19]

The purification method for an antibody composition according to claim 1, said method comprising:

loading the crude antibody product adjusted to a salt concentration of 0.5 M or more on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm to remove glycosylation isomers into a flow-through fraction;

washing the media with a wash buffer; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

[Claim 20]

The purification method for an antibody composition according to claim 1, said method comprising:

loading the crude antibody product adjusted to pH 4 to 6 on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm to remove glycosylation isomers into a flow-through fraction;

washing the media with a wash buffer; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

[Claim 21]

The method according to any one of claims 1 to 20, wherein the protein load per unit volume of the media of the conventional chromatography is 20 g/L or more, and the washing is accomplished by passing five or more column volumes of the wash buffer.

[Claim 22]

A production method for an antibody composition, which comprises the purification method according to any one of claims 1 to 21, wherein the ratio of an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region relative to the total antibody is 95% or more.

[Claim 23]

A production method for a purified anti-hDLK-1 antibody composition, whose

heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, said method comprising:

loading a crude antibody product on conventional chromatography with a media having a benzyl group or a butyl group and having a particle size of 20 to 100 μm ;

allowing an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media;

washing the media one or more times with a wash buffer containing 0.5 M or more salt to remove glycosylation isomers; and

eluting the antibody adsorbed to the media with an eluent of pH 5 to 7 having a salt concentration of 0.5 M or less or containing no salt to obtain a purified antibody composition,

wherein the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition is reduced when compared to the crude antibody product.

[Claim 24]

An antibody composition produced by the production method according to claim 22 or 23.

[Claim 25]

A method for removing glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region from a crude anti-hDLK-1 antibody product, whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, said method comprising:

Loading the crude antibody product on a hydrophobic interaction chromatography media to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media;

washing the media with a wash buffer; and

treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition.

[Claim 26]

An anti-hDLK-1 antibody composition, whose heavy chain has an amino acid sequence selected from SEQ ID NOS: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID NO: 12, wherein the antibody composition contains an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region at a ratio of 95% or more relative to the total antibody.

[Claim 27]

An anti-hDLK-1 antibody, whose heavy chain has an amino acid sequence selected from SEQ ID NOS: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or SEQ ID

NO: 12, wherein the antibody has no sugar chains attached to sites other than the Fc region glycosylation consensus region.

Fig. 1




Fig. 2






Fig. 3



HIC389

Fig. 4




Analyte	Peak 1 (%)	Peak 2 (%)	Peak 3 (%)
Loading sample	2. 1	12. 1	85. 8
Flow-through fraction	0	94. 2	5. 8
Elution fraction	0	0	100


Fig. 5A

Capto Butyl media

pH 4.5



pH 4.7



pH 5.0




Fig. 5B

Poros Benzyl Ultra media




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11

1 ATGGGTTGGAGCTGTATCATCTTCTTTCTGGTAGCAACAGCTACAGGCGTGCACTCCCAA
 M G W S C I I F F L V A T A T G V H S Q
 61 GTCCAGCTGGTGAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAAGTCTCC
 V Q L V Q S G A E V K K P G A S V K V S
 121 TGCAAGGCTTCCGGCTACACATTCACTGATTATGCTATGCACTGGGTGCGACAGGCCCTT
 C K A S G Y T F T D Y A M H W V R Q A P
 181 GGACAAGGCTGGAGTGGATTGGAGTTATTAGTACTTACTATGGTAATACAACTACAAC
 G Q G L E W I G V I S T Y Y G N T N Y N
 241 CAGAAGTTTAAGGGCAAGGCCACAATGACTGTGACACATCCACCAGCACAGCCTATATG
 Q K F K G K A T M T V D T S T S T A Y M
 301 GAACCTAGGAGCTTGAGATCTGACGATACTGCCGTGTATTACTGTGCAAGAGGAGGATTG
 E L R S L R S D D T A V Y Y C A R G G L
 361 CGAGAGTATTACTATGCTATGGACTACTGGGGTCAAGGAACCATGGTCACCGTCTCCTCA
 R E Y Y Y A M D Y W G Q G T M V T V S S
 421 GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGG
 A S T K G P S V F P L A P S S K S T S G
 481 GGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTGCG
 G T A A L G C L V K D Y F P E P V T V S
 541 TGGAACCTCAGGCGCCCTGACCAGCGGCGTGACACCTTCCCGGCTGTCTACAGTCCTCA
 W N S G A L T S G V H T F P A V L Q S S
 601 GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACC
 G L Y S L S S V V T V P S S S L G T Q T
 661 TACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
 Y I C N V N H K P S N T K V D K K V E P
 721 AAATCTTGTGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAACCTCTGGGGGGA
 K S C D K T H T C P P C P A P E L L G G
 781 CCGTCAGTCTTCTCTTCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCT
 P S V F L F P P K P K D T L M I S R T P
 841 GAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGG
 E V T C V V V D V S H E D P E V K F N W
 901 TACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
 Y V D G V E V H N A K T K P R E E Q Y N
 961 AGCACGTACCGTGTGGTGCAGCGTCTCACCGTCTGCACCAGGACTGGCTGAATGGCAAG
 S T Y R V V S V L T V L H Q D W L N G K
 1021 GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCATCGAGAAAACCATCTCC
 E Y K C K V S N K A L P A P I E K T I S
 1081 AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
 K A K G Q P R E P Q V Y T L P P S R D E
 1141 CTGACCAAGAACCAGGTGACCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATC
 L T K N Q V S L T C L V K G F Y P S D I
 1201 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACGCCTCCCGTG
 A V E W E S N G Q P E N N Y K T T P P V
 1261 CTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGG
 L D S D G S F F L Y S K L T V D K S R W
 1321 CAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAG
 Q Q G N V F S C S V M H E A L H N H Y T
 1381 CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
 Q K S L S L S P G K •

Fig. 12

1 ATGGGTTGGAGCTGTATCATCTTCTTTCTGGTAGCAACAGCTACAGGCGTGCACTCCCAA
 M G W S C I I F F L V A T A T G V H S Q
 61 GTCCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAAGTCTCC
 V Q L V Q S G A E V K K P G A S V K V S
 121 TGCAAGGCTTCCGGCTACACATTCAGTATTATGCTATGCACTGGGTGCGACAGGCCCT
 C K A S G Y T F T D Y A M H W V R Q A P
 181 GGACAAGGCTGGAGTGGATTGGAGTTATTAGTACTTACTATGGTAATACAACTACAAC
 G Q G L E W I G V I S T Y Y G N T N Y N
 241 CAGAAGTTTAAAGGGCCGAGCCACAATGACTGTGACACATCCACCAGCACAGCCTATATG
 Q K F K G R A T M T V D T S T S T A Y M
 301 GAACTTAGGAGCTTGAGATCTGACGATACTGCCGTGTATTACTGTGCAAGAGGAGGATTG
 E L R S L R S D D T A V Y Y C A R G G L
 361 CGAGAGTATTACTATGCTATGGACTACTGGGGTCAAGGAACCATGGTCACCGTCTCCTCA
 R E Y Y Y A M D Y W G Q G T M V T V S S
 421 GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGG
 A S T K G P S V F P L A P S S K S T S G
 481 GGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTGCG
 G T A A L G C L V K D Y F P E P V T V S
 541 TGGAAGTCAAGCGCCCTGACCAGCGCGTGCACACCTTCCCGGCTGTCTACAGTCCTCA
 W N S G A L T S G V H T F P A V L Q S S
 601 GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCTCCAGCAGCTTGGGGACCCAGACC
 G L Y S L S S V V T V P S S S L G T Q T
 661 TACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
 Y I C N V N H K P S N T K V D K K V E P
 721 AAATCTTGTGACAAACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGA
 K S C D K T H T C P P C P A P E L L G G
 781 CCGTCAGTCTTCTTCTTCCCCCAAACCAAGGACACCTCATGATCTCCCGGACCCCT
 P S V F L F P P K P K D T L M I S R T P
 841 GAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGG
 E V T C V V V D V S H E D P E V K F N W
 901 TACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
 Y V D G V E V H N A K T K P R E E Q Y N
 961 AGCAGTACCGTGTGGTCAAGCTCCTCACCGTCTGCAACAGGACTGGCTGAATGGCAAG
 S T Y R V V S V L T V L H Q D W L N G K
 1021 GAGTACAAGTCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
 E Y K C K V S N K A L P A P I E K T I S
 1081 AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
 K A K G Q P R E P Q V Y T L P P S R D E
 1141 CTGACCAAGAACCAGGTGACCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATC
 L T K N Q V S L T C L V K G F Y P S D I
 1201 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCTCCCGTG
 A V E W E S N G Q P E N N Y K T T P P V
 1261 CTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGG
 L D S D G S F F L Y S K L T V D K S R W
 1321 CAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAG
 Q Q G N V F S C S V M H E A L H N H Y T
 1381 CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
 Q K S L S L S P G K .

Fig. 13

```

1  ATGGAATCACAGACCCAGGTCCTCATGTTTCTTCTGCTCTGGGTATCTGGTGCCTGTGCA
   M E S Q T Q V L M F L L L W V S G A C A
61  GACATTGTCATGACACAGTCTCCAGACTCCCTGGCTGTGTCACTGGGAGAGAGGGCCACT
   D I V M T Q S P D S L A V S L G E R A T
121 ATCAACTGCAAGTCCAGTCAGAGCCTTCTGAATAGTAGCAATCAAAAGAACTATTTGGCC
   I N C K S S Q S L L N S S N Q K N Y L A
181 TGGTACCAGCAGAAACCAGGACAGCCTCCTAAACTTCTGGTCTACTTTGCATCCACTAGG
   W Y Q Q K P G Q P P K L L V Y F A S T R
241 GAATCTGGGGTCCCTGATCGCTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTTACC
   E S G V P D R F S G S G S G T D F T L T
301 ATCAGCAGTCTGCAGGCTGAAGATGTGGCAGTTTACTACTGTGCAGCAACATTATAGCACT
   I S S L Q A E D V A V Y Y C Q Q H Y S T
361 CCTCCACATTTCGGTCAGGGGACCAAGCTGGAGATCAAACGAACTGTGGCTGCACCATCT
   P P T F G Q G T K L E I K R T V A A P S
421 GTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAGTGCCTCTGTTGTGTGC
   V F I F P P S D E Q L K S G T A S V V C
481 CTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTC
   L L N N F Y P R E A K V Q W K V D N A L
541 CAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGC
   Q S G N S Q E S V T E Q D S K D S T Y S
601 CTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGC
   L S S T L T L S K A D Y E K H K V Y A C
661 GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
   E V T H Q G L S S P V T K S F N R G E C
721 TAG

```

.

Fig. 14

1 ATGGGTTGGAGCTGTATCATCTTCTTTCTGGTAGCAACAGCTACAGGCGTGCACTCCCAA
 M G W S C I I F F L V A T A T G V H S Q
 61 GTCCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAAGTCTCC
 V Q L V Q S G A E V K K P G A S V K V S
 121 TGCAAGGCTTCCGGCTACACATTCAGTATTATGCTATGCACTGGGTGCGACAGGCCCTT
 C K A S G Y T F T D Y A M H W V R Q A P
 181 GGACAAGGCTGGAGTGGATTGGAGTTATTAGTACTTACTATGGTAATACAACTACAAC
 G Q G L E W I G V I S T Y Y G N T N Y N
 241 CAGAAGTTTAAGGGCAAGGCCACAATGACTGTGACAAATCCACCAGCACAGCCTATATG
 Q K F K G K A T M T V D K S T S T A Y M
 301 GAACTTAGGAGCTTGAGATCTGACGATACTGCCGTGTATTACTGTGCAAGAGGAGGATTG
 E L R S L R S D D T A V Y Y C A R G G L
 361 CGAGAGTATTACTATGCTATGGACTACTGGGGTCAAGGAACCATGGTCACCGTCTCCTCA
 R E Y Y Y A M D Y W G Q G T M V T V S S
 421 GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGG
 A S T K G P S V F P L A P S S K S T S G
 481 GGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTGCG
 G T A A L G C L V K D Y F P E P V T V S
 541 TGGAACTCAGGCGCCCTGACCAGCGGCGTGACACCTTCCCGGCTGTCCTACAGTCCTCA
 W N S G A L T S G V H T F P A V L Q S S
 601 GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACC
 G L Y S L S S V V T V P S S S L G T Q T
 661 TACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
 Y I C N V N H K P S N T K V D K K V E P
 721 AAATCTTGTGACAAACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGA
 K S C D K T H T C P P C P A P E L L G G
 781 CCGTCAGTCTTCTTCTTCCCCCAAAACCAAGGACACCCTCATGATCTCCCGGACCCCT
 P S V F L F P P K P K D T L M I S R T P
 841 GAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGG
 E V T C V V V D V S H E D P E V K F N W
 901 TACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
 Y V D G V E V H N A K T K P R E E Q Y N
 961 AGCACGTACCGTGTGGTGCAGCGTCTCACCCTGTCACCAGGACTGGCTGAATGGCAAG
 S T Y R V V S V L T V L H Q D W L N G K
 1021 GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCC
 E Y K C K V S N K A L P A P I E K T I S
 1081 AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
 K A K G Q P R E P Q V Y T L P P S R D E
 1141 CTGACCAAGAACCAGGTGACCTGACCTGGTCAAAGGCTTCTATCCCAGCGACATC
 L T K N Q V S L T C L V K G F Y P S D I
 1201 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAACAACACTACAAGACCACGCCTCCCGTG
 A V E W E S N G Q P E N N Y K T T P P V
 1261 CTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGG
 L D S D G S F F L Y S K L T V D K S R W
 1321 CAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAG
 Q Q G N V F S C S V M H E A L H N H Y T
 1381 CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
 Q K S L S L S P G K •

Fig. 15

1 ATGGGTTGGAGCTGTATCATCTTCTTTCTGGTAGCAACAGCTACAGGCGTGCACTCCCAA
 M G W S C I I F F L V A T A T G V H S Q
 61 GTCCAGCTGGTGCAGTCTGGGGCTGAAGTGAAGAAGCCTGGGGCCTCAGTGAAAGTCTCC
 V Q L V Q S G A E V K K P G A S V K V S
 121 TGCAAGGGTTCCGGCTACACATTCAGTATTATGCTATGCACTGGGTGCGACAGGCCCT
 C K G S G Y T F T D Y A M H W V R Q A P
 181 GGACAAGGCCTGGAGTGGATTGGAGTTATTAGTACTTACTATGGTAATACAACTACAAC
 G Q G L E W I G V I S T Y Y G N T N Y N
 241 CAGAAGTTTAAGGGCAAGGCCACAATGACTGTGACAAATCCACCAGCACAGCCTATATG
 Q K F K G K A T M T V D K S T S T A Y M
 301 GAACTTAGGAGCTTGAGATCTGACGATACTGCCGTGTATTACTGTGCAAGAGGAGGATTG
 E L R S L R S D D T A V Y Y C A R G G L
 361 CGAGAGTATTACTATGCTATGGACTACTGGGGTCAAGGAACCATGGTCACCGTCTCCTCA
 R E Y Y Y A M D Y W G Q G T M V T V S S
 421 GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGG
 A S T K G P S V F P L A P S S K S T S G
 481 GGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTGCG
 G T A A L G C L V K D Y F P E P V T V S
 541 TGGAACTCAGGCGCCCTGACCAGCGCGTGCACACCTTCCGGCTGTCTACAGTCCTCA
 W N S G A L T S G V H T F P A V L Q S S
 601 GGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACC
 G L Y S L S S V V T V P S S S L G T Q T
 661 TACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCC
 Y I C N V N H K P S N T K V D K K V E P
 721 AAATCTTGTGACAAACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGA
 K S C D K T H T C P P C P A P E L L G G
 781 CCGTCAGTCTTCTCTTCCCCCAAACCCAAGGACACCCTCATGATCTCCCGGACCCCT
 P S V F L F P P K P K D T L M I S R T P
 841 GAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGG
 E V T C V V V D V S H E D P E V K F N W
 901 TACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAAC
 Y V D G V E V H N A K T K P R E E Q Y N
 961 AGCACGTACCGTGTGGTCAGCGTCTCACCCTGTCACCAGGACTGGCTGAATGGCAAG
 S T Y R V V S V L T V L H Q D W L N G K
 1021 GAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCC
 E Y K C K V S N K A L P A P I E K T I S
 1081 AAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAG
 K A K G Q P R E P Q V Y T L P P S R D E
 1141 CTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAGCGACATC
 L T K N Q V S L T C L V K G F Y P S D I
 1201 GCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCTCCCGTG
 A V E W E S N G Q P E N N Y K T T P P V
 1261 CTGGACTCCGACGGCTCCTTCTTCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGG
 L D S D G S F F L Y S K L T V D K S R W
 1321 CAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACAG
 Q Q G N V F S C S V M H E A L H N H Y T
 1381 CAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGA
 Q K S L S L S P G K .

17/17

	10	20	30	40	50	60
HuBA-1-3D-VH1 (4)						
HuBA-1-3D-VH1 A24G (16)						
HuBA-1-3D-VH1 T73K (20)						
HuBA-1-3D-VH1 A24G/T73K (24)						
HuBA-1-3D-VH2 (8)						
HuBA-1-3D-VH2 A24G (28)						
HuBA-1-3D-VH2 T73K (32)						
HuBA-1-3D-VH2 A24G/T73K (36)						

	70	80	90	100	110	120
HuBA-1-3D-VH1 (4)						
HuBA-1-3D-VH1 A24G (16)						
HuBA-1-3D-VH1 T73K (20)						
HuBA-1-3D-VH1 A24G/T73K (24)						
HuBA-1-3D-VH2 (8)						
HuBA-1-3D-VH2 A24G (28)						
HuBA-1-3D-VH2 T73K (32)						
HuBA-1-3D-VH2 A24G/T73K (36)						

SEQUENCE LISTING

<110> CHIOME Bioscience Inc.

<120> Purification method of antibody composition

<130> G2920W0

<150> JP 2021-079977

<151> 2021-05-10

<160> 78

<170> PatentIn version 3.5

<210> 1

<211> 420

<212> DNA

<213> Artificial

<220>

<223> Recombinant DNA

<220>

<221> CDS

<222> (1).. (420)

<400> 1

atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc	48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly	
1 5 10 15	

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag	96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys	
20 25 30	

cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc	144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe	
35 40 45	

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg	192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu	
50 55 60	

gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac	240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn	
65 70 75 80	

cag aag ttt aag ggc aag gcc aca atg act gtc gac aca tcc acc agc	288
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser	

85	90	95	
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg			336
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val			
100	105	110	
tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac			384
Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp			
115	120	125	
tac tgg ggt caa gga acc atg gtc acc gtc tcc tca			420
Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser			
130	135	140	

<210> 2

<211> 140

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 2

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
130 135 140

<210> 3
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1).. (363)

<400> 3
caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60
aag ggc aag gcc aca atg act gtc gac aca tcc acc agc aca gcc tat 240
Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

caa gga acc atg gtc acc gtc tcc tca
 Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

363

<210> 4
 <211> 121
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 5
 <211> 420
 <212> DNA

<213> Artificial

<220>

<223> Recombinant DNA

<220>

<221> CDS

<222> (1)..(420)

<400> 5

atg	ggc	tgg	agc	tgt	atc	atc	ttc	ttt	ctg	gta	gca	aca	gct	aca	ggc	48
Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly	
1			5						10					15		

gtg	cac	tcc	caa	gtc	cag	ctg	gtg	cag	tct	ggg	gct	gaa	gtg	aag	aag	96
Val	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	
			20					25					30			

cct	ggg	gcc	tca	gtg	aaa	gtc	tcc	tgc	aag	gct	tcc	ggc	tac	aca	ttc	144
Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	
		35					40					45				

act	gat	tat	gct	atg	cac	tgg	gtg	cga	cag	gcc	cct	gga	caa	ggc	ctg	192
Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	
	50					55					60					

gag	tgg	att	gga	gtt	att	agt	act	tac	tat	ggc	aat	aca	aac	tac	aac	240
Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn	
65				70						75					80	

cag	aag	ttt	aag	ggc	cga	gcc	aca	atg	act	gtc	gac	aca	tcc	acc	agc	288
Gln	Lys	Phe	Lys	Gly	Arg	Ala	Thr	Met	Thr	Val	Asp	Thr	Ser	Thr	Ser	
				85					90						95	

aca	gcc	tat	atg	gaa	ctt	agg	agc	ttg	aga	tct	gac	gat	act	gcc	gtg	336
Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	
			100					105						110		

tat	tac	tgt	gca	aga	gga	gga	ttg	cga	gag	tat	tac	tat	gct	atg	gac	384
Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp	
		115					120						125			

tac	tgg	ggc	caa	gga	acc	atg	gtc	acc	gtc	tcc	tca					420
Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser					
	130						135				140					

<210> 6

<211> 140

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 6

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
130 135 140

<210> 7

<211> 363

<212> DNA

<213> Artificial

<220>

<223> Recombinant DNA

<220>

<221> CDS

<222> (1).. (363)

<400> 7

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc	48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	

tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat	96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr	
20 25 30	

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att	144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile	
35 40 45	

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt	192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe	
50 55 60	

aag ggc cga gcc aca atg act gtc gac aca tcc acc agc aca gcc tat	240
Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr	
65 70 75 80	

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt	288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt	336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly	
100 105 110	

caa gga acc atg gtc acc gtc tcc tca	363
Gln Gly Thr Met Val Thr Val Ser Ser	
115 120	

<210> 8

<211> 121

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 8

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 9
<211> 399
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1).. (399)

<400> 9
atg gaa tca cag acc cag gtc ctc atg ttt ctt ctg ctc tgg gta tct 48
Met Glu Ser Gln Thr Gln Val Leu Met Phe Leu Leu Leu Trp Val Ser
1 5 10 15

ggt gcc tgt gca gac att gtc atg aca cag tct cca gac tcc ctg gct 96
Gly Ala Cys Ala Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
20 25 30

gtg tca ctg gga gag agg gcc act atc aac tgc aag tcc agt cag agc	144
Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser	
35 40 45	

ctt ctg aat agt agc aat caa aag aac tat ttg gcc tgg tac cag cag	192
Leu Leu Asn Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln	
50 55 60	

aaa cca gga cag cct cct aaa ctt ctg gtc tac ttt gca tcc act agg	240
Lys Pro Gly Gln Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg	
65 70 75 80	

gaa tct ggg gtc cct gat cgc ttc agt ggc agt gga tct ggg aca gat	288
Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp	
85 90 95	

ttc act ctt acc atc agc agt ctg cag gct gaa gat gtg gca gtt tac	336
Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr	
100 105 110	

tac tgt cag caa cat tat agc act cct ccc aca ttc ggt cag ggg acc	384
Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr	
115 120 125	

aag ctg gag atc aaa	399
Lys Leu Glu Ile Lys	
130	

<210> 10
 <211> 133
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 10

Met Glu Ser Gln Thr Gln Val Leu Met Phe Leu Leu Leu Trp Val Ser
1 5 10 15

Gly Ala Cys Ala Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
20 25 30

Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser
35 40 45

Leu Leu Asn Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln
50 55 60

Lys Pro Gly Gln Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg
65 70 75 80

Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
85 90 95

Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
100 105 110

Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr
115 120 125

Lys Leu Glu Ile Lys
130

<210> 11
<211> 339
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1).. (339)

<400> 11
gac att gtc atg aca cag tct cca gac tcc ctg gct gtg tca ctg gga 48
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

gag agg gcc act atc aac tgc aag tcc agt cag agc ctt ctg aat agt 96
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

agc aat caa aag aac tat ttg gcc tgg tac cag cag aaa cca gga cag 144
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

cct cct aaa ctt ctg gtc tac ttt gca tcc act agg gaa tct ggg gtc	192
Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val	
50 55 60	

cct gat cgc ttc agt ggc agt gga tct ggg aca gat ttc act ctt acc	240
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr	
65 70 75 80	

atc agc agt ctg cag gct gaa gat gtg gca gtt tac tac tgt cag caa	288
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln	
85 90 95	

cat tat agc act cct ccc aca ttc ggt cag ggg acc aag ctg gag atc	336
His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile	
100 105 110	

aaa	339
Lys	

<210> 12
 <211> 113
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 12

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
85 90 95

His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
100 105 110

Lys

<210> 13
<211> 420
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1)..(420)

<400> 13
atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30
cct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc 144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
35 40 45
act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60
gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80
cag aag ttt aag ggc aag gcc aca atg act gtc gac aca tcc acc agc 288
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser
85 90 95
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336

Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val		
			100					105					110				
tat	tac	tgt	gca	aga	gga	gga	ttg	cga	gag	tat	tac	tat	gct	atg	gac		384
Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp		
		115					120					125					
tac	tgg	ggt	caa	gga	acc	atg	gtc	acc	gtc	tcc	tca						420
Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser						
	130					135					140						

<210> 14
 <211> 140
 <212> PRT
 <213> Artificial

 <220>
 <223> Synthetic Construct

<400> 14

Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly
1				5					10					15	

Val	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys
			20					25					30		

Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe
		35					40					45			

Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu
	50					55					60				

Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn
65					70					75					80

Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Thr	Ser	Thr	Ser
				85					90					95	

Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val
			100					105					110		

Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

115

120

125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 130 135 140

<210> 15

<211> 363

<212> DNA

<213> Artificial

<220>

<223> Recombinant DNA

<220>

<221> CDS

<222> (1).. (363)

<400> 15

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat 96
 Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
 Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
 Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

aag ggc aag gcc aca atg act gtc gac aca tcc acc agc aca gcc tat 240
 Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
 Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

caa gga acc atg gtc acc gtc tcc tca 363
 Gln Gly Thr Met Val Thr Val Ser Ser

115

120

<210> 16
 <211> 121
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 16

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 17
 <211> 420
 <212> DNA
 <213> Artificial

<220>

$\langle 220 \rangle$

$\langle 222 \rangle$ (1) .. (420)

<400> 17

atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc 144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

cag aag ttt aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc 288
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac 384
Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

tac tgg ggt caa gga acc atg gtc acc gtc tcc tca 420
 Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 130 135 140

<210> 18

$\langle 211 \rangle$ 140

<212> PRT

<213> Artificial

$\langle 220 \rangle$

<223> Synthetic Construct

<400> 18

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
130 135 140

<210> 19

<211> 363

<212> DNA

<213> Artificial

<220>

<223> Recombinant DNA

<220>

<221> CDS

<222> (1).. (363)

<400> 19

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc	48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	

tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat	96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr	
20 25 30	

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att	144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile	
35 40 45	

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt	192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe	
50 55 60	

aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat	240
Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr	
65 70 75 80	

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt	288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt	336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly	
100 105 110	

caa gga acc atg gtc acc gtc tcc tca	363
Gln Gly Thr Met Val Thr Val Ser Ser	
115 120	

<210> 20

<211> 121

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 20

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr

20	25	30
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile		
35	40	45
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe		
50	55	60
Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr		
65	70	75
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys		
	85	90
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly		
	100	105
Gln Gly Thr Met Val Thr Val Ser Ser		
	115	120

<210> 21
 <211> 420
 <212> DNA
 <213> Artificial

<220>
 <223> Recombinant DNA

<220>
 <221> CDS
 <222> (1).. (420)

<400> 21	
atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc	48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly	
1 5 10 15	
gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag	96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys	
20 25 30	
cct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc	144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe	

35						40					45						
act	gat	tat	gct	atg	cac	tgg	gtg	cga	cag	gcc	cct	gga	caa	ggc	ctg	192	
Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu		
50						55					60						
gag	tgg	att	gga	gtt	att	agt	act	tac	tat	ggt	aat	aca	aac	tac	aac	240	
Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn		
65						70					75					80	
cag	aag	ttt	aag	ggc	aag	gcc	aca	atg	act	gtc	gac	aaa	tcc	acc	agc	288	
Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Thr	Ser		
						85					90					95	
aca	gcc	tat	atg	gaa	ctt	agg	agc	ttg	aga	tct	gac	gat	act	gcc	gtg	336	
Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val		
100						105					110						
tat	tac	tgt	gca	aga	gga	gga	ttg	cga	gag	tat	tac	tat	gct	atg	gac	384	
Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp		
115						120					125						
tac	tgg	ggt	caa	gga	acc	atg	gtc	acc	gtc	tcc	tca					420	
Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser						
130						135					140						

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
130 135 140

<210> 23
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1).. (363)

<400> 23

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat 240
Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

caa gga acc atg gtc acc gtc tcc tca 363
Gln Gly Thr Met Val Thr Val Ser Ser
115 120

$\langle 210 \rangle$	24
$\langle 211 \rangle$	121
$\langle 212 \rangle$	PRT
$\langle 213 \rangle$	Artificial

<220>
<223> Synthetic Construct

<400> 24

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 25
<211> 420
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1)..(420)

<400> 25
atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30
cct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc 144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
35 40 45
act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60
gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80
cag aag ttt aag ggc cga gcc aca atg act gtc gac aca tcc acc agc 288
Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser
85 90 95
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

tat	tac	tgt	gca	aga	gga	gga	ttg	cga	gag	tat	tac	tat	gct	atg	gac	384
Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp	
		115					120					125				

tac	tgg	ggt	caa	gga	acc	atg	gtc	acc	gtc	tcc	tca	420
Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	
	130					135					140	

<210> 26
 <211> 140
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 26

Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly
1				5					10						15

Val	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys
			20					25					30		

Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe
		35					40					45			

Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu
	50					55					60				

Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn
65					70					75					80

Gln	Lys	Phe	Lys	Gly	Arg	Ala	Thr	Met	Thr	Val	Asp	Thr	Ser	Thr	Ser
				85					90					95	

Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val
			100					105						110	

Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp
		115					120						125		

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
130 135 140

<210> 27
<211> 363
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>
<221> CDS
<222> (1).. (363)

<400> 27
caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60
aag ggc cga gcc aca atg act gtc gac aca tcc acc agc aca gcc tat 240
Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Tyr Cys
85 90 95
gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110
caa gga acc atg gtc acc gtc tcc tca 363
Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 28
<211> 121
<212> PRT
<213> Artificial

<220>
<223> Synthetic Construct

<400> 28

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 29
<211> 420
<212> DNA
<213> Artificial

<220>
<223> Recombinant DNA

<220>

<221> CDS

<222> (1).. (420)

<400> 29

atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly

1 5 10 15

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys

20 25 30

cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc 144

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu

50 55 60

gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn

65 70 75 80

cag aag ttt aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc 288

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser

85 90 95

aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val

100 105 110

tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac 384

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp

115 120 125

tac tgg ggt caa gga acc atg gtc acc gtc tcc tca 420

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser

130 135 140

<210> 30

<211> 140

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 30

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
 65 70 75 80

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser
 85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
 100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
 115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 130 135 140

<210> 31
 <211> 363
 <212> DNA
 <213> Artificial

<220>
 <223> Recombinant DNA

<220>
 <221> CDS
 <222> (1).. (363)

<400> 31

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat 240
Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

caa gga acc atg gtc acc gtc tcc tca 363
Gln Gly Thr Met Val Thr Val Ser Ser
115 120

$\langle 210 \rangle$	32
$\langle 211 \rangle$	121
$\langle 212 \rangle$	PRT
$\langle 213 \rangle$	Artificial

<220>
<223> Synthetic Construct

<400> 32

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 33
 <211> 420
 <212> DNA
 <213> Artificial

<220>
 <223> Recombinant DNA

<220>
 <221> CDS
 <222> (1).. (420)

<400> 33
 atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
 Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

cct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc 144
 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
 35 40 45

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192

Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	
50						55					60					
gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac																240
Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn	
65					70					75					80	
cag aag ttt aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc																288
Gln	Lys	Phe	Lys	Gly	Arg	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Thr	Ser	
				85					90					95		
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg																336
Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	
			100					105					110			
tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac																384
Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp	
		115					120					125				
tac tgg ggt caa gga acc atg gtc acc gtc tcc tca																420
Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser					
	130					135					140					

<210> 34
 <211> 140
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 34

Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly
1				5					10					15	

Val	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys
			20					25					30		

Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe
		35					40					45			

Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu
50						55					60				

Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

65 70 75 80

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
130 135 140

$\langle 210 \rangle$	35
$\langle 211 \rangle$	363
$\langle 212 \rangle$	DNA
$\langle 213 \rangle$	Artificial
$\langle 220 \rangle$	
$\langle 223 \rangle$	Recombinant DNA

$\langle 220 \rangle$
 $\langle 221 \rangle$ CDS
 $\langle 222 \rangle$ (1) .. (363)

[illegible]

65	70	75	80	
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt	288			
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys				
85 90 95				
gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt	336			
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly				
100 105 110				
caa gga acc atg gtc acc gtc tcc tca	363			
Gln Gly Thr Met Val Thr Val Ser Ser				
115 120				

<210> 36
 <211> 121
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 36

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser
 115 120

<210> 37
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1413)

<400> 37
 atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
 Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15
 gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30
 cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc 144
 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45
 act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
 Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60
 gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
 Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
 65 70 75 80
 cag aag ttt aag ggc aag gcc aca atg act gtc gac aca tcc acc agc 288
 Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser
 85 90 95
 aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336
 Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
 100 105 110
 tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac 384
 Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
 115 120 125

tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140	432
ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160	480
ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175	528
gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190	576
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205	624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220	672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240	720
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255	768
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270	816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285	864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300	912
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320	960
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp	1008

325	330	335	
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca			1056
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro			
340	345	350	
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa			1104
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu			
355	360	365	
cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac			1152
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn			
370	375	380	
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc			1200
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile			
385	390	395	400
gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc			1248
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr			
405	410	415	
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag			1296
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys			
420	425	430	
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc			1344
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys			
435	440	445	
tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc			1392
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu			
450	455	460	
tcc ctg tct ccg ggt aaa tga			1413
Ser Leu Ser Pro Gly Lys			
465	470		

<210> 38
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 38

Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly
1				5					10						15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn

210					215					220					
Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro
225					230					235					240
Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu
				245					250					255	
Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp
			260					265						270	
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp
		275					280					285			
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly
	290					295					300				
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn
305					310					315					320
Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp
				325					330					335	
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro
			340					345					350		
Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu
		355					360					365			
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn
	370					375					380				
Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile
385					390					395					400
Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr
				405					410					415	

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210> 39
<211> 1356
<212> DNA
<213> Artificial Sequence

<220>
<223> antibody

<220>
<221> CDS
<222> (1).. (1356)

<400> 39
caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60
aag ggc aag gcc aca atg act gtc gac aca tcc acc agc aca gcc tat 240
Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288

Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys		
				85					90					95			
gca	aga	gga	gga	ttg	cga	gag	tat	tac	tat	gct	atg	gac	tac	tgg	ggt		336
Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp	Tyr	Trp	Gly		
			100					105					110				
caa	gga	acc	atg	gtc	acc	gtc	tcc	tca	gcc	tcc	acc	aag	ggc	cca	tcg		384
Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser		
		115					120					125					
gtc	ttc	ccc	ctg	gca	ccc	tcc	tcc	aag	agc	acc	tct	ggg	ggc	aca	gcg		432
Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala		
		130				135					140						
gcc	ctg	ggc	tgc	ctg	gtc	aag	gac	tac	ttc	ccc	gaa	ccg	gtg	acg	gtg		480
Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val		
145					150					155					160		
tcg	tgg	aac	tca	ggc	gcc	ctg	acc	agc	ggc	gtg	cac	acc	ttc	ccg	gct		528
Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala		
			165					170					175				
gtc	cta	cag	tcc	tca	gga	ctc	tac	tcc	ctc	agc	agc	gtg	gtg	acc	gtg		576
Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val		
			180					185					190				
ccc	tcc	agc	agc	ttg	ggc	acc	cag	acc	tac	atc	tgc	aac	gtg	aat	cac		624
Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His		
		195					200					205					
aag	ccc	agc	aac	acc	aag	gtg	gac	aag	aaa	gtt	gag	ccc	aaa	tct	tgt		672
Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys		
	210					215				220							
gac	aaa	act	cac	aca	tgc	cca	ccg	tgc	cca	gca	cct	gaa	ctc	ctg	ggg		720
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly		
225					230					235					240		
gga	ccg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg		768
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met		
			245						250					255			
atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac	gtg	agc	cac		816
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His		
			260					265					270				
gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc	gtg	gag	gtg		864
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val		
		275					280					285					

cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365	1104
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380	1152
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400	1200
gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415	1248
gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430	1296
cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445	1344
ccg ggt aaa tga Pro Gly Lys 450	1356

<210> 40
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 40

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Lys
450

<210> 41
<211> 1413
<212> DNA
<213> Artificial Sequence

<220>
<223> antibody

<220>
<221> CDS
<222> (1).. (1413)

<400> 41
atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15
gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30
cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc 144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45
act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60
gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

cag aag ttt aag ggc cga gcc aca atg act gtc gac aca tcc acc agc Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser 85 90 95	288
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val 100 105 110	336
tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp 115 120 125	384
tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140	432
ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160	480
ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175	528
gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190	576
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205	624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220	672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240	720
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255	768
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270	816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 280 285 290 295 300	864

275	280	285	
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300			912
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320			960
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335			1008
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350			1056
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365			1104
cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 370 375 380			1152
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400			1200
gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415			1248
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430			1296
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445			1344
tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460			1392
tcc ctg tct ccg ggt aaa tga Ser Leu Ser Pro Gly Lys 465 470			1413

<210> 42
<211> 470
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 42

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro

	165		170		175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr	180		185		190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val	195		200		205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn	210		215		220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro	225		230		235
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu	245		250		255
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp	260		265		270
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp	275		280		285
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly	290		295		300
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn	305		310		315
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp	325		330		335
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro	340		345		350
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu	355		360		365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
 370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 43
 <211> 1356
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1356)

<400> 43
 caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat 96
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile	
35 40 45	
gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt	192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe	
50 55 60	
aag ggc cga gcc aca atg act gtc gac aca tcc acc agc aca gcc tat	240
Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr	
65 70 75 80	
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt	288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt	336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly	
100 105 110	
caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg	384
Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser	
115 120 125	
gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg	432
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala	
130 135 140	
gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg	480
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val	
145 150 155 160	
tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct	528
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala	
165 170 175	
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg	576
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val	
180 185 190	
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac	624
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His	
195 200 205	
aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt	672
Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys	
210 215 220	
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg	720
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly	
225 230 235 240	

gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365	1104
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380	1152
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400	1200
gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415	1248
gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430	1296
cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445	1344

ccg ggt aaa tga
Pro Gly Lys
450

1356

<210> 44
<211> 451
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 44

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 45
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1).. (1413)

<400> 45	
atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc	48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly	
1 5 10 15	
gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag	96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys	
20 25 30	

cct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe 35 40 45	144
act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60	192
gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn 65 70 75 80	240
cag aag ttt aag ggc aag gcc aca atg act gtc gac aca tcc acc agc Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser 85 90 95	288
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val 100 105 110	336
tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp 115 120 125	384
tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140	432
ggc cca tog gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160	480
ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175	528
gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190	576
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205	624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220	672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240	720

225	230	235	240	
aaa tct tgt gac Lys Ser Cys Asp	aaa act cac aca tgc Lys Thr His Thr Cys	cca ccg tgc cca gca cct Pro Pro Cys Pro Ala Pro	gaa Glu	768
	245	250	255	
ctc ctg ggg gga ccg tca gtc ttc Leu Leu Gly Gly Pro Ser Val Phe	ctc ttc ccc cca aaa ccc aag Leu Phe Pro Pro Lys Pro Lys	gac Asp		816
	260	265	270	
acc ctc atg atc tcc ccg acc cct gag gtc Thr Leu Met Ile Ser Arg Thr Pro Glu Val	aca tgc gtg gtg gtg gac Thr Cys Val Val Val Asp			864
	275	280	285	
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly				912
	290	295	300	
gtg gag gtg cat aat gcc aag aca aag ccg ccg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn				960
	305	310	315	320
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp				1008
	325	330	335	
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro				1056
	340	345	350	
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu				1104
	355	360	365	
cca cag gtg tac acc ctg ccc cca tcc ccg gat gag ctg acc aag aac Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn				1152
	370	375	380	
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile				1200
	385	390	395	400
gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr				1248
	405	410	415	
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys				1296
	420	425	430	
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc				1344

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc 1392
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

tcc ctg tct ccg ggt aaa tga 1413
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 46
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 46

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
 35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
 65 70 75 80

Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser
 85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
 100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp

115		120		125
Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys				
130		135		140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly				
145		150		155
				160
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro				
		165		170
				175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr				
		180		185
				190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val				
		195		200
				205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn				
		210		215
				220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro				
225		230		235
				240
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu				
		245		250
				255
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp				
		260		265
				270
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp				
		275		280
				285
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly				
		290		295
				300
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn				
305		310		315
				320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210> 47
<211> 1356
<212> DNA
<213> Artificial Sequence

<220>
<223> antibody

<220>
<221> CDS

<222> (1)..(1356)

<400> 47

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc	48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	

tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat	96
Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr	
20 25 30	

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att	144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile	
35 40 45	

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt	192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe	
50 55 60	

aag ggc aag gcc aca atg act gtc gac aca tcc acc agc aca gcc tat	240
Lys Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr	
65 70 75 80	

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt	288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt	336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly	
100 105 110	

caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg	384
Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser	
115 120 125	

gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg	432
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala	
130 135 140	

gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg	480
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val	
145 150 155 160	

tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct	528
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala	
165 170 175	

gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg	576
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val	
180 185 190	

ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205	624
aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220	672
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240	720
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365	1104
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380	1152
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400	1200

gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	1248
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	
				405					410					415		

gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	1296
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	
			420					425						430		

cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	1344
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	
		435					440							445		

ccg	ggt	aaa	tga	1356
Pro	Gly	Lys		
	450			

<210> 48
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 48

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	

Ser	Val	Lys	Val	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe	Thr	Asp	Tyr
			20					25					30		

Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	Ile
		35					40					45			

Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn	Gln	Lys	Phe
	50					55					60				

Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Thr	Ser	Thr	Ser	Thr	Ala	Tyr
65					70					75					80

Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
				85					90					95	

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 49
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>

<221> CDS

<222> (1).. (1413)

<400> 49

atg	ggt	tgg	agc	tgt	atc	atc	ttc	ttt	ctg	gta	gca	aca	gct	aca	ggc	48
Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly	
1				5					10					15		

gtg	cac	tcc	caa	gtc	cag	ctg	gtg	cag	tct	ggg	gct	gaa	gtg	aag	aag	96
Val	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	
			20					25					30			

cct	ggg	gcc	tca	gtg	aaa	gtc	tcc	tgc	aag	ggg	tcc	ggc	tac	aca	ttc	144
Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe	
		35					40					45				

act	gat	tat	gct	atg	cac	tgg	gtg	cga	cag	gcc	cct	gga	caa	ggc	ctg	192
Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	
	50					55					60					

gag	tgg	att	gga	gtt	att	agt	act	tac	tat	ggg	aat	aca	aac	tac	aac	240
Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn	
65				70						75					80	

cag	aag	ttt	aag	ggc	cga	gcc	aca	atg	act	gtc	gac	aca	tcc	acc	agc	288
Gln	Lys	Phe	Lys	Gly	Arg	Ala	Thr	Met	Thr	Val	Asp	Thr	Ser	Thr	Ser	
			85					90						95		

aca	gcc	tat	atg	gaa	ctt	agg	agc	ttg	aga	tct	gac	gat	act	gcc	gtg	336
Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val	
			100					105						110		

tat	tac	tgt	gca	aga	gga	gga	ttg	cga	gag	tat	tac	tat	gct	atg	gac	384
Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp	
		115					120						125			

tac	tgg	ggg	caa	gga	acc	atg	gtc	acc	gtc	tcc	tca	gcc	tcc	acc	aag	432
Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	
	130					135					140					

ggc	cca	tcg	gtc	ttc	ccc	ctg	gca	ccc	tcc	tcc	aag	agc	acc	tct	ggg	480
Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	
145					150					155					160	

ggc	aca	gcg	gcc	ctg	ggc	tgc	ctg	gtc	aag	gac	tac	ttc	ccc	gaa	ccg	528
Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	
			165					170						175		

gtg	acg	gtg	tcg	tgg	aac	tca	ggc	gcc	ctg	acc	agc	ggc	gtg	cac	acc	576
Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	

180	185	190	
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205			624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220			672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240			720
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255			768
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270			816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285			864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly 290 295 300			912
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 305 310 315 320			960
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335			1008
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 340 345 350			1056
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365			1104
cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 370 375 380			1152
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc			1200

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc 1248
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1296
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc 1344
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc 1392
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

tcc ctg tct ccg ggt aaa tga 1413
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 50
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 50

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
 35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn

65		70		75		80
Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser						
		85		90		95
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val						
		100		105		110
Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp						
		115		120		125
Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys						
		130		135		140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly						
		145		150		155
						160
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro						
		165		170		175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr						
		180		185		190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val						
		195		200		205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn						
		210		215		220
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro						
		225		230		235
						240
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu						
		245		250		255
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp						
		260		265		270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210> 51
 <211> 1356
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1356)

<400> 51
 caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat 96
 Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
 Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
 Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60
 aag ggc cga gcc aca atg act gtc gac aca tcc acc agc aca gcc tat 240
 Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
 Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
 100 105 110
 caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg 384
 Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125
 gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg 432
 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160	480
tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175	528
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190	576
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205	624
aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220	672
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240	720
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056

tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc	1104
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser	
355 360 365	

ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag	1152
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu	
370 375 380	

tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc	1200
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro	
385 390 395 400	

gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg	1248
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val	
405 410 415	

gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg	1296
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met	
420 425 430	

cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct	1344
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser	
435 440 445	

ccg ggt aaa tga	1356
Pro Gly Lys	
450	

<210> 52
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 52

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Lys

<210> 53
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1413)

<400> 53
 atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
 Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc 144
 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
 Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60

gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
 Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
 65 70 75 80

cag aag ttt aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc 288
 Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser
 85 90 95

aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336
 Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
 100 105 110

tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac 384
 Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
 115 120 125

tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag 432
 Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys

130	135	140	
ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg			480
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly			
145	150	155	160
ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg			528
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro			
	165	170	175
gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc			576
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr			
	180	185	190
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg			624
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val			
	195	200	205
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac			672
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn			
	210	215	220
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc			720
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro			
	225	230	235
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa			768
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu			
	245	250	255
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac			816
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp			
	260	265	270
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac			864
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp			
	275	280	285
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc			912
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly			
	290	295	300
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac			960
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn			
	305	310	315
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg			1008
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp			
	325	330	335
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca			1056

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro	
340 345 350	
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa	1104
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu	
355 360 365	
cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac	1152
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn	
370 375 380	
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc	1200
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile	
385 390 395 400	
gcc gtg gag tgg gag agc aat ggg cag cgg gag aac aac tac aag acc	1248
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr	
405 410 415	
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag	1296
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys	
420 425 430	
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc	1344
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys	
435 440 445	
tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc	1392
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu	
450 455 460	
tcc ctg tct ccg ggt aaa tga	1413
Ser Leu Ser Pro Gly Lys	
465 470	

<210> 54
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 54

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys

20	25	30
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe		
35	40	45
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu		
50	55	60
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn		
65	70	75
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser		
85	90	95
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val		
100	105	110
Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp		
115	120	125
Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys		
130	135	140
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly		
145	150	155
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro		
165	170	175
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr		
180	185	190
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val		
195	200	205
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn		
210	215	220

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
260 265 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 55
 <211> 1356
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1356)

<400> 55
 caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat 96
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
 Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45
 gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
 Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60
 aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat 240
 Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110	336
caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125	384
gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140	432
gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160	480
tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175	528
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190	576
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205	624
aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220	672
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240	720
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912

cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc	960
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly	
305 310 315 320	
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc	1008
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile	
325 330 335	
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg	1056
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val	
340 345 350	
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc	1104
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser	
355 360 365	
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag	1152
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu	
370 375 380	
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc	1200
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro	
385 390 395 400	
gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg	1248
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val	
405 410 415	
gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg	1296
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met	
420 425 430	
cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct	1344
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser	
435 440 445	
ccg ggt aaa tga	1356
Pro Gly Lys	
450	

<210> 56
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 56

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
 100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
 115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
 130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
 145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
 165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
 180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
 195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val

405

410

415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445

Pro Gly Lys
 450

<210> 57
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1).. (1413)

<400> 57
 atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
 Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

cct ggg gcc tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc 144
 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
 Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60

gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
 Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
 65 70 75 80

cag aag ttt aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc 288
 Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser

85	90	95	
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val 100 105 110			336
tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp 115 120 125			384
tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys 130 135 140			432
ggc cca tog gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly 145 150 155 160			480
ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175			528
gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190			576
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205			624
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn 210 215 220			672
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro 225 230 235 240			720
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255			768
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270			816
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285			864
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc			912

Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly		
290						295					300						
gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	cgg	gag	gag	cag	tac	aac		960
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn		
305					310					315					320		
agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg		1008
Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp		
				325					330					335			
ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca		1056
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro		
			340					345					350				
gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa		1104
Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu		
		355					360					365					
cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac		1152
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn		
		370				375					380						
cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc		1200
Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile		
385					390					395					400		
gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc		1248
Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr		
				405				410						415			
acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag		1296
Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys		
			420					425					430				
ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc		1344
Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys		
		435					440					445					
tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc		1392
Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu		
		450				455					460						
tcc	ctg	tct	ccg	ggt	aaa	tga											1413
Ser	Leu	Ser	Pro	Gly	Lys												
465					470												

<210> 58
 <211> 470
 <212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 58

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
210 215 220

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
260 265 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

Ser Leu Ser Pro Gly Lys
 465 470

<210> 59
 <211> 1356
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1356)

<400> 59
 caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

tca gtg aaa gtc tcc tgc aag gct tcc ggc tac aca ttc act gat tat 96
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
 Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
 35 40 45

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe 50 55 60	192
aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80	240
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95	288
gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly 100 105 110	336
caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125	384
gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140	432
gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160	480
tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175	528
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190	576
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205	624
aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220	672
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240	720
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768

atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365	1104
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380	1152
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400	1200
gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415	1248
gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430	1296
cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445	1344
ccg ggt aaa tga Pro Gly Lys	1356

450

<210> 60
<211> 451
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<400> 60

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser

355 360 365
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445
 Pro Gly Lys
 450

<210> 61
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(1413)

<400> 61
 atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
 Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15
 gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
 Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30
 oct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc 144
 Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe

35	40	45	
act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg			192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu			
50	55	60	
gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac			240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn			
65	70	75	80
cag aag ttt aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc			288
Gln Lys Phe Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser			
	85	90	95
aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg			336
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val			
	100	105	110
tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac			384
Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp			
	115	120	125
tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag			432
Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys			
	130	135	140
ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg			480
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly			
145	150	155	160
ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg			528
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro			
	165	170	175
gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc			576
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr			
	180	185	190
ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg			624
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val			
	195	200	205
gtg acc gtg ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac			672
Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn			
	210	215	220
gtg aat cac aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc			720
Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro			
225	230	235	240
aaa tct tgt gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa			768

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu	
245 250 255	
ctc ctg ggg gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac	816
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp	
260 265 270	
acc ctc atg atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac	864
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp	
275 280 285	
gtg agc cac gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc	912
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly	
290 295 300	
gtg gag gtg cat aat gcc aag aca aag ccg cgg gag gag cag tac aac	960
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn	
305 310 315 320	
agc acg tac cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg	1008
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp	
325 330 335	
ctg aat ggc aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca	1056
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro	
340 345 350	
gcc ccc atc gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa	1104
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu	
355 360 365	
cca cag gtg tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac	1152
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn	
370 375 380	
cag gtc agc ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc	1200
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile	
385 390 395 400	
gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc	1248
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr	
405 410 415	
acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag	1296
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys	
420 425 430	
ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc	1344
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys	
435 440 445	

tcc	gtg	atg	cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	1392
Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	
	450					455					460					

tcc	ctg	tct	ccg	ggt	aaa	tga	1413
Ser	Leu	Ser	Pro	Gly	Lys		
465				470			

<210> 62
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 62

Met	Gly	Trp	Ser	Cys	Ile	Ile	Phe	Phe	Leu	Val	Ala	Thr	Ala	Thr	Gly
1				5					10					15	

Val	His	Ser	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys
			20					25					30		

Pro	Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Gly	Ser	Gly	Tyr	Thr	Phe
		35					40					45			

Thr	Asp	Tyr	Ala	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu
	50					55					60				

Glu	Trp	Ile	Gly	Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn
65					70					75					80

Gln	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Met	Thr	Val	Asp	Lys	Ser	Thr	Ser
				85					90					95	

Thr	Ala	Tyr	Met	Glu	Leu	Arg	Ser	Leu	Arg	Ser	Asp	Asp	Thr	Ala	Val
			100					105					110		

Tyr	Tyr	Cys	Ala	Arg	Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp
		115					120						125		

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
210 215 220

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
260 265 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210> 63
<211> 1356
<212> DNA
<213> Artificial Sequence

<220>
<223> antibody

<220>
<221> CDS
<222> (1).. (1356)

<400> 63

caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc	48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala	
1 5 10 15	
tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat	96
Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr	
20 25 30	
gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att	144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile	
35 40 45	
gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt	192
Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe	
50 55 60	
aag ggc aag gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat	240
Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr	
65 70 75 80	
atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt	288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt	336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly	
100 105 110	
caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg	384
Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser	
115 120 125	
gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg	432
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala	
130 135 140	
gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg	480
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val	
145 150 155 160	
tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct	528
Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala	
165 170 175	
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg	576
Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val	
180 185 190	
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac	624
Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His	
195 200 205	

aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220	672
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240	720
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056
tac acc ctg ccc cca tcc ccg gat gag ctg acc aag aac cag gtc agc Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365	1104
ctg acc tgc ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380	1152
tgg gag agc aat ggg cag ccg gag aac aac tac aag acc acg cct ccc Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400	1200
gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 1248	

405	410	415	
gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg			1296
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met			
420	425	430	
cat gag gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct			1344
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser			
435	440	445	
ccg ggt aaa tga			1356
Pro Gly Lys			
450			

<210> 64
 <211> 451
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 64

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Lys Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly

305		310		315		320
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile						
		325		330		335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val						
		340		345		350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser						
		355		360		365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu						
		370		375		380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro						
		385		390		395
						400
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val						
		405		410		415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met						
		420		425		430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser						
		435		440		445
Pro Gly Lys						
		450				

<210> 65
 <211> 1413
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1).. (1413)

<400> 65
atg ggt tgg agc tgt atc atc ttc ttt ctg gta gca aca gct aca ggc 48
Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
1 5 10 15

gtg cac tcc caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag 96
Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

cct ggg gcc tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc 144
Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
35 40 45

act gat tat gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg 192
Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
50 55 60

gag tgg att gga gtt att agt act tac tat ggt aat aca aac tac aac 240
Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
65 70 75 80

cag aag ttt aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc 288
Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

aca gcc tat atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg 336
Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

tat tac tgt gca aga gga gga ttg cga gag tat tac tat gct atg gac 384
Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

tac tgg ggt caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag 432
Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140

ggc cca tcg gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg 480
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160

ggc aca gcg gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg 528
Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175

gtg acg gtg tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc 576
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190

ttc ccg gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg 624

Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val		
	195						200					205					
gtg	acc	gtg	ccc	tcc	agc	agc	ttg	ggc	acc	cag	acc	tac	atc	tgc	aac		672
Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn		
	210					215					220						
gtg	aat	cac	aag	ccc	agc	aac	acc	aag	gtg	gac	aag	aaa	gtt	gag	ccc		720
Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro		
	225				230					235					240		
aaa	tct	tgt	gac	aaa	act	cac	aca	tgc	cca	ccg	tgc	cca	gca	cct	gaa		768
Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu		
				245					250					255			
ctc	ctg	ggg	gga	cgg	tca	gtc	ttc	ctc	ttc	ccc	cca	aaa	ccc	aag	gac		816
Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp		
			260					265						270			
acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	aca	tgc	gtg	gtg	gtg	gac		864
Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp		
	275						280					285					
gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	aac	tgg	tac	gtg	gac	ggc		912
Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly		
	290					295				300							
gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	cgg	cgg	gag	gag	cag	tac	aac		960
Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn		
	305				310					315					320		
agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	gtc	ctg	cac	cag	gac	tgg		1008
Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp		
				325					330					335			
ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	tcc	aac	aaa	gcc	ctc	cca		1056
Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro		
			340					345					350				
gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	aaa	ggg	cag	ccc	cga	gaa		1104
Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu		
		355					360					365					
cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	gat	gag	ctg	acc	aag	aac		1152
Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn		
	370					375					380						
cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc		1200
Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile		
	385				390					395					400		

gcc gtg gag tgg gag agc aat ggg cag ccg gag aac aac tac aag acc 1248
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
 405 410 415

acg cct ccc gtg ctg gac tcc gac ggc tcc ttc ttc ctc tac agc aag 1296
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 420 425 430

ctc acc gtg gac aag agc agg tgg cag cag ggg aac gtc ttc tca tgc 1344
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
 435 440 445

tcc gtg atg cat gag gct ctg cac aac cac tac acg cag aag agc ctc 1392
 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
 450 455 460

tcc ctg tct ccg ggt aaa tga 1413
 Ser Leu Ser Pro Gly Lys
 465 470

<210> 66
 <211> 470
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 66

Met Gly Trp Ser Cys Ile Ile Phe Phe Leu Val Ala Thr Ala Thr Gly
 1 5 10 15

Val His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
 20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe
 35 40 45

Thr Asp Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
 50 55 60

Glu Trp Ile Gly Val Ile Ser Thr Tyr Tyr Gly Asn Thr Asn Tyr Asn
 65 70 75 80

Gln Lys Phe Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser
85 90 95

Thr Ala Tyr Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp
115 120 125

Tyr Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys
130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro
165 170 175

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr
180 185 190

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val
195 200 205

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn
210 215 220

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro
225 230 235 240

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu
245 250 255

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
260 265 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
450 455 460

Ser Leu Ser Pro Gly Lys
465 470

<210> 67
<211> 1356

<212> DNA
<213> Artificial Sequence

<220>
<223> antibody

<220>
<221> CDS
<222> (1)..(1356)

<400> 67
caa gtc cag ctg gtg cag tct ggg gct gaa gtg aag aag cct ggg gcc 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

tca gtg aaa gtc tcc tgc aag ggt tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

gct atg cac tgg gtg cga cag gcc cct gga caa ggc ctg gag tgg att 144
Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

gga gtt att agt act tac tat ggt aat aca aac tac aac cag aag ttt 192
Gly Val Ile Ser Thr Tyr Gly Asn Thr Asn Tyr Asn Gln Lys Phe
50 55 60

aag ggc cga gcc aca atg act gtc gac aaa tcc acc agc aca gcc tat 240
Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

atg gaa ctt agg agc ttg aga tct gac gat act gcc gtg tat tac tgt 288
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

gca aga gga gga ttg cga gag tat tac tat gct atg gac tac tgg ggt 336
Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

caa gga acc atg gtc acc gtc tcc tca gcc tcc acc aag ggc cca tcg 384
Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

gtc ttc ccc ctg gca ccc tcc tcc aag agc acc tct ggg ggc aca gcg 432
Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

gcc ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg acg gtg 480
Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

tcg tgg aac tca ggc gcc ctg acc agc ggc gtg cac acc ttc ccg gct Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175	528
gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg acc gtg Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190	576
ccc tcc agc agc ttg ggc acc cag acc tac atc tgc aac gtg aat cac Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205	624
aag ccc agc aac acc aag gtg gac aag aaa gtt gag ccc aaa tct tgt Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220	672
gac aaa act cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240	720
gga ccg tca gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255	768
atc tcc cgg acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270	816
gaa gac cct gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285	864
cat aat gcc aag aca aag ccg cgg gag gag cag tac aac agc acg tac His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300	912
cgt gtg gtc agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320	960
aag gag tac aag tgc aag gtc tcc aac aaa gcc ctc cca gcc ccc atc Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335	1008
gag aaa acc atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350	1056
tac acc ctg ccc cca tcc cgg gat gag ctg acc aag aac cag gtc agc Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser	1104

355							360				365										
ctg	acc	tgc	ctg	gtc	aaa	ggc	ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	1152					
Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu						
370							375				380										
tgg	gag	agc	aat	ggg	cag	ccg	gag	aac	aac	tac	aag	acc	acg	cct	ccc	1200					
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro						
385							390				395							400			
gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	1248					
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val						
405							410							415							
gac	aag	agc	agg	tgg	cag	cag	ggg	aac	gtc	ttc	tca	tgc	tcc	gtg	atg	1296					
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met						
420							425							430							
cat	gag	gct	ctg	cac	aac	cac	tac	acg	cag	aag	agc	ctc	tcc	ctg	tct	1344					
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser						
435							440							445							
ccg	ggt	aaa	tga													1356					
Pro	Gly	Lys																			
450																					

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ala Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Lys Gly Arg Ala Thr Met Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Gly Gly Leu Arg Glu Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser
115 120 125

Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala
130 135 140

Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val
145 150 155 160

Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala
165 170 175

Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val
180 185 190

Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His
195 200 205

Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys
210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
225 230 235 240

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His

260	265	270
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val		
275	280	285
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr		
290	295	300
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly		
305	310	315
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile		
325	330	335
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val		
340	345	350
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser		
355	360	365
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu		
370	375	380
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro		
385	390	395
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val		
405	410	415
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met		
420	425	430
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser		
435	440	445
Pro Gly Lys		
450		

<210> 69
 <211> 723
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> antibody

<220>
 <221> CDS
 <222> (1)..(723)

<400> 69
 atg gaa tca cag acc cag gtc ctc atg ttt ctt ctg ctc tgg gta tct 48
 Met Glu Ser Gln Thr Gln Val Leu Met Phe Leu Leu Leu Trp Val Ser
 1 5 10 15

ggt gcc tgt gca gac att gtc atg aca cag tct cca gac tcc ctg gct 96
 Gly Ala Cys Ala Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala
 20 25 30

gtg tca ctg gga gag agg gcc act atc aac tgc aag tcc agt cag agc 144
 Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser
 35 40 45

ctt ctg aat agt agc aat caa aag aac tat ttg gcc tgg tac cag cag 192
 Leu Leu Asn Ser Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln
 50 55 60

aaa cca gga cag cct cct aaa ctt ctg gtc tac ttt gca tcc act agg 240
 Lys Pro Gly Gln Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg
 65 70 75 80

gaa tct ggg gtc cct gat cgc ttc agt ggc agt gga tct ggg aca gat 288
 Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
 85 90 95

ttc act ctt acc atc agc agt ctg cag gct gaa gat gtg gca gtt tac 336
 Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
 100 105 110

tac tgt cag caa cat tat agc act cct ccc aca ttc ggt cag ggg acc 384
 Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr
 115 120 125

aag ctg gag atc aaa cga act gtg gct gca cca tct gtc ttc atc ttc 432
 Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
 130 135 140

ccg cca tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg tgc 480

Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly	Thr	Ala	Ser	Val	Val	Cys	
145					150					155					160	
ctg	ctg	aat	aac	ttc	tat	ccc	aga	gag	gcc	aaa	gta	cag	tgg	aag	gtg	528
Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	Lys	Val	Gln	Trp	Lys	Val	
				165					170					175		
gat	aac	gcc	ctc	caa	tcg	ggt	aac	tcc	cag	gag	agt	gtc	aca	gag	cag	576
Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser	Gln	Glu	Ser	Val	Thr	Glu	Gln	
			180					185					190			
gac	agc	aag	gac	agc	acc	tac	agc	ctc	agc	agc	acc	ctg	acg	ctg	agc	624
Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	
		195					200					205				
aaa	gca	gac	tac	gag	aaa	cac	aaa	gtc	tac	gcc	tgc	gaa	gtc	acc	cat	672
Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	Cys	Glu	Val	Thr	His	
	210					215				220						
cag	ggc	ctg	agc	tcg	ccc	gtc	aca	aag	agc	ttc	aac	agg	gga	gag	tgt	720
Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys	Ser	Phe	Asn	Arg	Gly	Glu	Cys	
225					230					235					240	
tag																723

<210> 70
 <211> 240
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 70

Met	Glu	Ser	Gln	Thr	Gln	Val	Leu	Met	Phe	Leu	Leu	Leu	Trp	Val	Ser
1				5					10					15	

Gly	Ala	Cys	Ala	Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Asp	Ser	Leu	Ala
			20					25					30		

Val	Ser	Leu	Gly	Glu	Arg	Ala	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser
		35					40					45			

Leu	Leu	Asn	Ser	Ser	Asn	Gln	Lys	Asn	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln
	50					55					60				

Lys Pro Gly Gln Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg
65 70 75 80

Glu Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
85 90 95

Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
100 105 110

Tyr Cys Gln Gln His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr
115 120 125

Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe
130 135 140

Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys
145 150 155 160

Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val
165 170 175

Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln
180 185 190

Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
195 200 205

Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His
210 215 220

Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235 240

<210> 71

<211> 663

<212> DNA

<213> Artificial Sequence

<220>

<223> antibody

<220>

<221> CDS

<222> (1)..(663)

<400> 71

gac att gtc atg aca cag tct cca gac tcc ctg gct gtg tca ctg gga	48
Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly	
1 5 10 15	

gag agg gcc act atc aac tgc aag tcc agt cag agc ctt ctg aat agt	96
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser	
20 25 30	

agc aat caa aag aac tat ttg gcc tgg tac cag cag aaa cca gga cag	144
Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln	
35 40 45	

cct cct aaa ctt ctg gtc tac ttt gca tcc act agg gaa tct ggg gtc	192
Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val	
50 55 60	

cct gat cgc ttc agt ggc agt gga tct ggg aca gat ttc act ctt acc	240
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr	
65 70 75 80	

atc agc agt ctg cag gct gaa gat gtg gca gtt tac tac tgt cag caa	288
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln	
85 90 95	

cat tat agc act cct ccc aca ttc ggt cag ggg acc aag ctg gag atc	336
His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile	
100 105 110	

aaa cga act gtg gct gca cca tct gtc ttc atc ttc ccg cca tct gat	384
Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp	
115 120 125	

gag cag ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg aat aac	432
Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn	
130 135 140	

ttc tat ccc aga gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc	480
Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu	
145 150 155 160	

caa tcg ggt aac tcc cag gag agt gtc aca gag cag gac agc aag gac	528
Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp	
165 170 175	

agc acc tac agc ctc agc agc acc ctg acg ctg agc aaa gca gac tac 576
 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
 180 185 190

gag aaa cac aaa gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc 624
 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
 195 200 205

tcg ccc gtc aca aag agc ttc aac agg gga gag tgt tag 663
 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 210 215 220

<210> 72
 <211> 220
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Construct

<400> 72

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
 20 25 30

Ser Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45

Pro Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
 85 90 95

His Tyr Ser Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
 100 105 110

Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
115 120 125

Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
130 135 140

Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
145 150 155 160

Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
165 170 175

Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
180 185 190

Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
195 200 205

Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215 220

<210> 73
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> CDRH1

<400> 73

Asp Tyr Ala Met His
1 5

<210> 74
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> CDRH2

<400> 74

Val	Ile	Ser	Thr	Tyr	Tyr	Gly	Asn	Thr	Asn	Tyr	Asn	Gln	Lys	Phe	Lys
1				5					10					15	

Gly

<210> 75

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> CDRH3

<400> 75

Gly	Gly	Leu	Arg	Glu	Tyr	Tyr	Tyr	Ala	Met	Asp	Tyr
1				5					10		

<210> 76

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CDRL1

<400> 76

Lys	Ser	Ser	Gln	Ser	Leu	Leu	Asn	Ser	Ser	Asn	Gln	Lys	Asn	Tyr	Leu
1				5					10					15	

Ala

<210> 77

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> CDRL2

<400> 77

Phe Ala Ser Thr Arg Glu Ser
1 5

<210> 78
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> CDRL3

<400> 78

Gln Gln His Tyr Ser Thr Pro Pro Thr
1 5